{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T18:33:42Z","timestamp":1792175622667,"version":"4.4.0"},"reference-count":226,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T00:00:00Z","timestamp":1670457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T00:00:00Z","timestamp":1670457600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biomed"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Vaccines are one of the most effective medical interventions to combat newly emerging and re-emerging diseases. Prophylactic vaccines against rabies, measles, etc., have excellent effectiveness in preventing viral infection and associated diseases. However, the host immune response is unable to inhibit virus replication or eradicate established diseases in most infected people. Therapeutic vaccines, expressing specific endogenous or exogenous antigens, mainly induce or boost cell-mediated immunity via provoking cytotoxic T cells or elicit humoral immunity via activating B cells to produce specific antibodies. The ultimate aim of a therapeutic vaccine is to reshape the host immunity for eradicating a disease and establishing lasting memory. Therefore, therapeutic vaccines have been developed for the treatment of some infectious diseases and chronic noncommunicable diseases. Various technological strategies have been implemented for the development of therapeutic vaccines, including molecular-based vaccines (peptide\/protein, DNA and mRNA vaccines), vector-based vaccines (bacterial vector vaccines, viral vector vaccines and yeast-based vaccines) and cell-based vaccines (dendritic cell vaccines and genetically modified cell vaccines) as well as combinatorial approaches. This review mainly summarizes therapeutic vaccine-induced immunity and describes the development and status of multiple types of therapeutic vaccines against infectious diseases, such as those caused by HPV, HBV, HIV, HCV, and SARS-CoV-2, and chronic noncommunicable diseases, including cancer, hypertension, Alzheimer\u2019s disease, amyotrophic lateral sclerosis, diabetes, and dyslipidemia, that have been evaluated in recent preclinical and clinical studies.<\/jats:p>","DOI":"10.1186\/s43556-022-00098-9","type":"journal-article","created":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T03:02:16Z","timestamp":1670468536000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":66,"title":["Development of therapeutic vaccines for the treatment of diseases"],"prefix":"10.1186","volume":"3","author":[{"given":"Yaomei","family":"Tian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Die","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhua","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,8]]},"reference":[{"key":"98_CR1","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1007\/bf03391594","volume":"32","author":"U Schlipk\u00f6ter","year":"2010","unstructured":"Schlipk\u00f6ter U, Flahault A. Communicable diseases: achievements and challenges for public health. Public Health Rev. 2010;32:90\u2013119. https:\/\/doi.org\/10.1007\/bf03391594.","journal-title":"Public Health Rev"},{"issue":"4","key":"98_CR2","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/s41591-021-01301-0","volume":"27","author":"JL Excler","year":"2021","unstructured":"Excler JL, Saville M, Berkley S, Kim JH. Vaccine development for emerging infectious diseases. Nat Med. 2021;27(4):591\u2013600. https:\/\/doi.org\/10.1038\/s41591-021-01301-0.","journal-title":"Nat Med"},{"issue":"11","key":"98_CR3","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1086\/652404","volume":"201","author":"GA Weinberg","year":"2010","unstructured":"Weinberg GA, Szilagyi PG. Vaccine epidemiology: efficacy, effectiveness, and the translational research roadmap. J Infect Dis. 2010;201(11):1607\u201310. https:\/\/doi.org\/10.1086\/652404.","journal-title":"J Infect Dis"},{"issue":"2","key":"98_CR4","doi-asserted-by":"publisher","first-page":"100","DOI":"10.34172\/ijhpm.2021.49","volume":"11","author":"A Binagwaho","year":"2022","unstructured":"Binagwaho A, Mathewos K, Davis S. Equitable and effective distribution of the COVID-19 vaccines - a scientific and moral obligation. Int J Health Policy Manag. 2022;11(2):100\u20132. https:\/\/doi.org\/10.34172\/ijhpm.2021.49.","journal-title":"Int J Health Policy Manag"},{"issue":"45","key":"98_CR5","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.15585\/mmwr.mm7045e1","volume":"70","author":"KR Woodworth","year":"2021","unstructured":"Woodworth KR, Moulia D, Collins JP, Hadler SC, Jones JM, Reddy SC, et al. The advisory committee on immunization Practices' interim recommendation for use of Pfizer-BioNTech COVID-19 vaccine in children aged 5\u201311 years - United States, November 2021. MMWR Morb Mortal Wkly Rep. 2021;70(45):1579\u201383. https:\/\/doi.org\/10.15585\/mmwr.mm7045e1.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"98_CR6","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.bpobgyn.2017.09.008","volume":"47","author":"G Hancock","year":"2018","unstructured":"Hancock G, Hellner K, Dorrell L. Therapeutic HPV vaccines. Best Pract Res Clin Obstet Gynaecol. 2018;47:59\u201372. https:\/\/doi.org\/10.1016\/j.bpobgyn.2017.09.008.","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"issue":"3","key":"98_CR7","doi-asserted-by":"publisher","first-page":"153","DOI":"10.22088\/cjim.8.3.153","volume":"8","author":"J Masrour-Roudsari","year":"2017","unstructured":"Masrour-Roudsari J, Ebrahimpour S. Causal role of infectious agents in cancer: an overview. Caspian J Intern Med. 2017;8(3):153\u20138. https:\/\/doi.org\/10.22088\/cjim.8.3.153.","journal-title":"Caspian J Intern Med"},{"issue":"10","key":"98_CR8","doi-asserted-by":"publisher","first-page":"e1295","DOI":"10.1016\/s2214-109x(19)30370-5","volume":"7","author":"JJ Bigna","year":"2019","unstructured":"Bigna JJ, Noubiap JJ. The rising burden of non-communicable diseases in sub-Saharan Africa. Lancet Glob Health. 2019;7(10):e1295\u20136. https:\/\/doi.org\/10.1016\/s2214-109x(19)30370-5.","journal-title":"Lancet Glob Health"},{"issue":"3","key":"98_CR9","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.trstmh.2005.07.021","volume":"100","author":"A Boutayeb","year":"2006","unstructured":"Boutayeb A. The double burden of communicable and non-communicable diseases in developing countries. Trans R Soc Trop Med Hyg. 2006;100(3):191\u20139. https:\/\/doi.org\/10.1016\/j.trstmh.2005.07.021.","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"1","key":"98_CR10","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s12929-016-0293-9","volume":"23","author":"A Yang","year":"2016","unstructured":"Yang A, Farmer E, Wu TC, Hung CF. Perspectives for therapeutic HPV vaccine development. J Biomed Sci. 2016;23(1):75. https:\/\/doi.org\/10.1186\/s12929-016-0293-9.","journal-title":"J Biomed Sci"},{"issue":"5","key":"98_CR11","doi-asserted-by":"publisher","first-page":"309","DOI":"10.3322\/caac.20132","volume":"62","author":"JM Kirkwood","year":"2012","unstructured":"Kirkwood JM, Butterfield LH, Tarhini AA, Zarour H, Kalinski P, Ferrone S. Immunotherapy of cancer in 2012. CA Cancer J Clin. 2012;62(5):309\u201335. https:\/\/doi.org\/10.3322\/caac.20132.","journal-title":"CA Cancer J Clin"},{"issue":"15","key":"98_CR12","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1016\/j.vaccine.2021.03.017","volume":"39","author":"JD Williamson","year":"2021","unstructured":"Williamson JD, Gould KG, Brown K. Richard Pfeiffer's typhoid vaccine and Almroth Wright's claim to priority. Vaccine. 2021;39(15):2074\u20139. https:\/\/doi.org\/10.1016\/j.vaccine.2021.03.017.","journal-title":"Vaccine."},{"issue":"10","key":"98_CR13","doi-asserted-by":"publisher","first-page":"907","DOI":"10.2217\/fon-2017-0531","volume":"14","author":"CE Handy","year":"2018","unstructured":"Handy CE, Antonarakis ES. Sipuleucel-T for the treatment of prostate cancer: novel insights and future directions. Future Oncol. 2018;14(10):907\u201317. https:\/\/doi.org\/10.2217\/fon-2017-0531.","journal-title":"Future Oncol"},{"issue":"11","key":"98_CR14","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1253\/circj.CJ-20-0703","volume":"84","author":"R Nakamaru","year":"2020","unstructured":"Nakamaru R, Nakagami H, Rakugi H, Morishita R. Future directions of therapeutic vaccines for chronic diseases. Circ J. 2020;84(11):1895\u2013902. https:\/\/doi.org\/10.1253\/circj.CJ-20-0703.","journal-title":"Circ J"},{"issue":"1","key":"98_CR15","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13045-022-01247-x","volume":"15","author":"J Liu","year":"2022","unstructured":"Liu J, Fu M, Wang M, Wan D, Wei Y, Wei X. Cancer vaccines as promising immuno-therapeutics: platforms and current progress. J Hematol Oncol. 2022;15(1):28. https:\/\/doi.org\/10.1186\/s13045-022-01247-x.","journal-title":"J Hematol Oncol"},{"issue":"6","key":"98_CR16","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/s41568-021-00346-0","volume":"21","author":"M Saxena","year":"2021","unstructured":"Saxena M, van der Burg SH, Melief CJM, Bhardwaj N. Therapeutic cancer vaccines. Nat Rev Cancer. 2021;21(6):360\u201378. https:\/\/doi.org\/10.1038\/s41568-021-00346-0.","journal-title":"Nat Rev Cancer"},{"issue":"9","key":"98_CR17","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/nrd2994","volume":"8","author":"Rethinking therapeutic cancer vaccines","year":"2009","unstructured":"Rethinking therapeutic cancer vaccines. Nat Rev Drug Discov. 2009;8(9):685\u20136. https:\/\/doi.org\/10.1038\/nrd2994.","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"98_CR18","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1038\/nrc.2018.13","volume":"18","author":"RBS Roden","year":"2018","unstructured":"Roden RBS, Stern PL. Opportunities and challenges for human papillomavirus vaccination in cancer. Nat Rev Cancer. 2018;18(4):240\u201354. https:\/\/doi.org\/10.1038\/nrc.2018.13.","journal-title":"Nat Rev Cancer"},{"issue":"Suppl 1","key":"98_CR19","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1159\/000333258","volume":"81","author":"BK Kim","year":"2011","unstructured":"Kim BK, Han KH, Ahn SH. Prevention of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Oncology. 2011;81(Suppl 1):41\u20139. https:\/\/doi.org\/10.1159\/000333258.","journal-title":"Oncology."},{"issue":"6","key":"98_CR20","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.arcmed.2009.07.003","volume":"40","author":"L Gissmann","year":"2009","unstructured":"Gissmann L, Nieto K. The therapeutic vaccine: is it feasible? Arch Med Res. 2009;40(6):493\u20138. https:\/\/doi.org\/10.1016\/j.arcmed.2009.07.003.","journal-title":"Arch Med Res"},{"key":"98_CR21","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41541-019-0103-y","volume":"4","author":"RE Hollingsworth","year":"2019","unstructured":"Hollingsworth RE, Jansen K. Turning the corner on therapeutic cancer vaccines. NPJ Vaccines. 2019;4:7. https:\/\/doi.org\/10.1038\/s41541-019-0103-y.","journal-title":"NPJ Vaccines"},{"issue":"11","key":"98_CR22","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1038\/sj.onc.1210791","volume":"27","author":"N H\u00e4fner","year":"2008","unstructured":"H\u00e4fner N, Driesch C, Gajda M, Jansen L, Kirchmayr R, Runnebaum IB, et al. Integration of the HPV16 genome does not invariably result in high levels of viral oncogene transcripts. Oncogene. 2008;27(11):1610\u20137. https:\/\/doi.org\/10.1038\/sj.onc.1210791.","journal-title":"Oncogene."},{"issue":"1","key":"98_CR23","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s12943-019-1055-6","volume":"18","author":"M Peng","year":"2019","unstructured":"Peng M, Mo Y, Wang Y, Wu P, Zhang Y, Xiong F, et al. Neoantigen vaccine: an emerging tumor immunotherapy. Mol Cancer. 2019;18(1):128. https:\/\/doi.org\/10.1186\/s12943-019-1055-6.","journal-title":"Mol Cancer"},{"issue":"18","key":"98_CR24","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1016\/j.vaccine.2017.03.049","volume":"35","author":"Y Lobaina","year":"2017","unstructured":"Lobaina Y, Michel ML. Chronic hepatitis B: immunological profile and current therapeutic vaccines in clinical trials. Vaccine. 2017;35(18):2308\u201314. https:\/\/doi.org\/10.1016\/j.vaccine.2017.03.049.","journal-title":"Vaccine."},{"issue":"Pt 6","key":"98_CR25","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1099\/0022-1317-74-6-945","volume":"74","author":"MS Campo","year":"1993","unstructured":"Campo MS, Grindlay GJ, O'Neil BW, Chandrachud LM, McGarvie GM, Jarrett WF. Prophylactic and therapeutic vaccination against a mucosal papillomavirus. J Gen Virol. 1993;74(Pt 6):945\u201353. https:\/\/doi.org\/10.1099\/0022-1317-74-6-945.","journal-title":"J Gen Virol"},{"key":"98_CR26","doi-asserted-by":"publisher","first-page":"106944","DOI":"10.1016\/j.intimp.2020.106944","volume":"88","author":"M Shahnazari","year":"2020","unstructured":"Shahnazari M, Samadi P, Pourjafar M, Jalali A. Therapeutic vaccines for colorectal cancer: the progress and future prospect. Int Immunopharmacol. 2020;88:106944. https:\/\/doi.org\/10.1016\/j.intimp.2020.106944.","journal-title":"Int Immunopharmacol"},{"issue":"6","key":"98_CR27","doi-asserted-by":"publisher","first-page":"629","DOI":"10.2174\/0929867053202188","volume":"12","author":"E Lazoura","year":"2005","unstructured":"Lazoura E, Apostolopoulos V. Rational peptide-based vaccine design for cancer immunotherapeutic applications. Curr Med Chem. 2005;12(6):629\u201339. https:\/\/doi.org\/10.2174\/0929867053202188.","journal-title":"Curr Med Chem"},{"issue":"3","key":"98_CR28","doi-asserted-by":"publisher","first-page":"624","DOI":"10.3390\/vaccines2030624","volume":"2","author":"T Ura","year":"2014","unstructured":"Ura T, Okuda K, Shimada M. Developments in viral vector-based vaccines. Vaccines (Basel). 2014;2(3):624\u201341. https:\/\/doi.org\/10.3390\/vaccines2030624.","journal-title":"Vaccines (Basel)"},{"key":"98_CR29","doi-asserted-by":"publisher","unstructured":"Kumar R, Kumar P. Yeast-based vaccines: new perspective in vaccine development and application. FEMS Yeast Res. 2019;19(2). https:\/\/doi.org\/10.1093\/femsyr\/foz007.","DOI":"10.1093\/femsyr\/foz007"},{"issue":"2","key":"98_CR30","doi-asserted-by":"publisher","first-page":"443","DOI":"10.4049\/jimmunol.1701024","volume":"200","author":"PM Santos","year":"2018","unstructured":"Santos PM, Butterfield LH. Dendritic cell-based cancer vaccines. J Immunol. 2018;200(2):443\u20139. https:\/\/doi.org\/10.4049\/jimmunol.1701024.","journal-title":"J Immunol"},{"issue":"5","key":"98_CR31","doi-asserted-by":"publisher","first-page":"2843","DOI":"10.3892\/or.2016.5128","volume":"36","author":"D Xue","year":"2016","unstructured":"Xue D, Liang Y, Duan S, He J, Su J, Zhu J, et al. Enhanced anti-tumor immunity against breast cancer induced by whole tumor cell vaccines genetically modified expressing \u03b1-gal epitopes. Oncol Rep. 2016;36(5):2843\u201351. https:\/\/doi.org\/10.3892\/or.2016.5128.","journal-title":"Oncol Rep"},{"key":"98_CR32","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3389\/fimmu.2019.00008","volume":"10","author":"K Vermaelen","year":"2019","unstructured":"Vermaelen K. Vaccine strategies to improve anti-cancer cellular immune responses. Front Immunol. 2019;10:8. https:\/\/doi.org\/10.3389\/fimmu.2019.00008.","journal-title":"Front Immunol"},{"issue":"6","key":"98_CR33","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/s41573-021-00163-y","volume":"20","author":"B Pulendran","year":"2021","unstructured":"Pulendran B, Arunachalam PS, O'Hagan DT. Emerging concepts in the science of vaccine adjuvants. Nat Rev Drug Discov. 2021;20(6):454\u201375. https:\/\/doi.org\/10.1038\/s41573-021-00163-y.","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"98_CR34","doi-asserted-by":"publisher","first-page":"e74","DOI":"10.1038\/cti.2016.19","volume":"5","author":"F Liang","year":"2016","unstructured":"Liang F, Lor\u00e9 K. Local innate immune responses in the vaccine adjuvant-injected muscle. Clin Transl Immunology. 2016;5(4):e74. https:\/\/doi.org\/10.1038\/cti.2016.19.","journal-title":"Clin Transl Immunology"},{"key":"98_CR35","doi-asserted-by":"publisher","unstructured":"Liang F, Lindgren G, Sandgren KJ, Thompson EA, Francica JR, Seubert A, et al. Vaccine priming is restricted to draining lymph nodes and controlled by adjuvant-mediated antigen uptake. Sci Transl Med. 2017;9(393). https:\/\/doi.org\/10.1126\/scitranslmed.aal2094.","DOI":"10.1126\/scitranslmed.aal2094"},{"issue":"9","key":"98_CR36","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1016\/j.vaccine.2010.12.090","volume":"29","author":"S Calabro","year":"2011","unstructured":"Calabro S, Tortoli M, Baudner BC, Pacitto A, Cortese M, O'Hagan DT, et al. Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes. Vaccine. 2011;29(9):1812\u201323. https:\/\/doi.org\/10.1016\/j.vaccine.2010.12.090.","journal-title":"Vaccine."},{"issue":"4","key":"98_CR37","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.4049\/jimmunol.1400948","volume":"193","author":"AM Didierlaurent","year":"2014","unstructured":"Didierlaurent AM, Collignon C, Bourguignon P, Wouters S, Fierens K, Fochesato M, et al. Enhancement of adaptive immunity by the human vaccine adjuvant AS01 depends on activated dendritic cells. J Immunol. 2014;193(4):1920\u201330. https:\/\/doi.org\/10.4049\/jimmunol.1400948.","journal-title":"J Immunol"},{"key":"98_CR38","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.3389\/fimmu.2018.01484","volume":"9","author":"L Gornati","year":"2018","unstructured":"Gornati L, Zanoni I, Granucci F. Dendritic cells in the cross hair for the generation of tailored vaccines. Front Immunol. 2018;9:1484. https:\/\/doi.org\/10.3389\/fimmu.2018.01484.","journal-title":"Front Immunol"},{"issue":"6","key":"98_CR39","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1016\/j.cell.2015.08.004","volume":"162","author":"S Eickhoff","year":"2015","unstructured":"Eickhoff S, Brewitz A, Gerner MY, Klauschen F, Komander K, Hemmi H, et al. Robust anti-viral immunity requires multiple distinct T cell-dendritic cell interactions. Cell. 2015;162(6):1322\u201337. https:\/\/doi.org\/10.1016\/j.cell.2015.08.004.","journal-title":"Cell."},{"issue":"4","key":"98_CR40","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/s41579-021-00639-z","volume":"20","author":"RE Baker","year":"2022","unstructured":"Baker RE, Mahmud AS, Miller IF, Rajeev M, Rasambainarivo F, Rice BL, et al. Infectious disease in an era of global change. Nat Rev Microbiol. 2022;20(4):193\u2013205. https:\/\/doi.org\/10.1038\/s41579-021-00639-z.","journal-title":"Nat Rev Microbiol"},{"key":"98_CR41","doi-asserted-by":"publisher","first-page":"167","DOI":"10.2147\/itt.S273327","volume":"9","author":"C Smalley Rumfield","year":"2020","unstructured":"Smalley Rumfield C, Roller N, Pellom ST, Schlom J, Jochems C. Therapeutic vaccines for HPV-associated malignancies. Immunotargets Ther. 2020;9:167\u2013200. https:\/\/doi.org\/10.2147\/itt.S273327.","journal-title":"Immunotargets Ther"},{"issue":"2","key":"98_CR42","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1111\/cei.13614","volume":"205","author":"T Cargill","year":"2021","unstructured":"Cargill T, Barnes E. Therapeutic vaccination for treatment of chronic hepatitis B. Clin Exp Immunol. 2021;205(2):106\u201318. https:\/\/doi.org\/10.1111\/cei.13614.","journal-title":"Clin Exp Immunol"},{"key":"98_CR43","doi-asserted-by":"publisher","unstructured":"Hokello J, Sharma AL, Tyagi M. An update on the HIV DNA vaccine strategy. Vaccines (Basel). 2021;9(6). https:\/\/doi.org\/10.3390\/vaccines9060605.","DOI":"10.3390\/vaccines9060605"},{"key":"98_CR44","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.pvr.2017.12.006","volume":"5","author":"A Chabeda","year":"2018","unstructured":"Chabeda A, Yanez RJR, Lamprecht R, Meyers AE, Rybicki EP, Hitzeroth II. Therapeutic vaccines for high-risk HPV-associated diseases. Papillomavirus Res. 2018;5:46\u201358. https:\/\/doi.org\/10.1016\/j.pvr.2017.12.006.","journal-title":"Papillomavirus Res"},{"issue":"5","key":"98_CR45","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/nrc798","volume":"2","author":"H zur Hausen","year":"2002","unstructured":"zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer. 2002;2(5):342\u201350. https:\/\/doi.org\/10.1038\/nrc798.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"98_CR46","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12985-021-01732-8","volume":"19","author":"X Wang","year":"2022","unstructured":"Wang X, Song Y, Wei X, Wang G, Sun R, Wang M, et al. Prevalence and distribution of human papillomavirus genotypes among women attending gynecology clinics in northern Henan Province of China. Virol J. 2022;19(1):6. https:\/\/doi.org\/10.1186\/s12985-021-01732-8.","journal-title":"Virol J"},{"issue":"6","key":"98_CR47","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1007\/s00109-022-02199-y","volume":"100","author":"N Khairkhah","year":"2022","unstructured":"Khairkhah N, Bolhassani A, Najafipour R. Current and future direction in treatment of HPV-related cervical disease. J Mol Med (Berl). 2022;100(6):829\u201345. https:\/\/doi.org\/10.1007\/s00109-022-02199-y.","journal-title":"J Mol Med (Berl)"},{"key":"98_CR48","doi-asserted-by":"publisher","first-page":"188","DOI":"10.3389\/fimmu.2020.00188","volume":"11","author":"AR Garbuglia","year":"2020","unstructured":"Garbuglia AR, Lapa D, Sias C, Capobianchi MR, Del Porto P. The use of both therapeutic and prophylactic vaccines in the therapy of papillomavirus disease. Front Immunol. 2020;11:188. https:\/\/doi.org\/10.3389\/fimmu.2020.00188.","journal-title":"Front Immunol"},{"issue":"2","key":"98_CR49","doi-asserted-by":"publisher","first-page":"212.e1","DOI":"10.1016\/j.ajog.2016.02.021","volume":"215","author":"A Hildesheim","year":"2016","unstructured":"Hildesheim A, Gonzalez P, Kreimer AR, Wacholder S, Schussler J, Rodriguez AC, et al. Impact of human papillomavirus (HPV) 16 and 18 vaccination on prevalent infections and rates of cervical lesions after excisional treatment. Am J Obstet Gynecol. 2016;215(2):212.e1\u2013212.e15. https:\/\/doi.org\/10.1016\/j.ajog.2016.02.021.","journal-title":"Am J Obstet Gynecol"},{"issue":"3","key":"98_CR50","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1586\/erv.13.23","volume":"12","author":"MP Morrow","year":"2013","unstructured":"Morrow MP, Yan J, Sardesai NY. Human papillomavirus therapeutic vaccines: targeting viral antigens as immunotherapy for precancerous disease and cancer. Expert Rev Vaccines. 2013;12(3):271\u201383. https:\/\/doi.org\/10.1586\/erv.13.23.","journal-title":"Expert Rev Vaccines"},{"issue":"30","key":"98_CR51","doi-asserted-by":"publisher","first-page":"3975","DOI":"10.1016\/j.vaccine.2009.04.041","volume":"27","author":"PC Maciag","year":"2009","unstructured":"Maciag PC, Radulovic S, Rothman J. The first clinical use of a live-attenuated listeria monocytogenes vaccine: a phase I safety study of lm-LLO-E7 in patients with advanced carcinoma of the cervix. Vaccine. 2009;27(30):3975\u201383. https:\/\/doi.org\/10.1016\/j.vaccine.2009.04.041.","journal-title":"Vaccine."},{"issue":"10","key":"98_CR52","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1016\/j.micinf.2007.05.005","volume":"9","author":"P Schnupf","year":"2007","unstructured":"Schnupf P, Portnoy DA. Listeriolysin O: a phagosome-specific lysin. Microbes Infect. 2007;9(10):1176\u201387. https:\/\/doi.org\/10.1016\/j.micinf.2007.05.005.","journal-title":"Microbes Infect"},{"issue":"4","key":"98_CR53","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1097\/igc.0000000000001235","volume":"28","author":"P Basu","year":"2018","unstructured":"Basu P, Mehta A, Jain M, Gupta S, Nagarkar RV, John S, et al. A randomized phase 2 study of ADXS11-001 listeria monocytogenes-Listeriolysin O immunotherapy with or without Cisplatin in treatment of advanced cervical cancer. Int J Gynecol Cancer. 2018;28(4):764\u201372. https:\/\/doi.org\/10.1097\/igc.0000000000001235.","journal-title":"Int J Gynecol Cancer"},{"issue":"47","key":"98_CR54","doi-asserted-by":"publisher","first-page":"6233","DOI":"10.1016\/j.vaccine.2014.09.020","volume":"32","author":"K Kawana","year":"2014","unstructured":"Kawana K, Adachi K, Kojima S, Taguchi A, Tomio K, Yamashita A, et al. Oral vaccination against HPV E7 for treatment of cervical intraepithelial neoplasia grade 3 (CIN3) elicits E7-specific mucosal immunity in the cervix of CIN3 patients. Vaccine. 2014;32(47):6233\u20139. https:\/\/doi.org\/10.1016\/j.vaccine.2014.09.020.","journal-title":"Vaccine."},{"key":"98_CR55","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.omtm.2019.08.005","volume":"15","author":"SS Taghinezhad","year":"2019","unstructured":"Taghinezhad SS, Mohseni AH, Keyvani H, Razavi MR. Phase 1 safety and immunogenicity trial of recombinant Lactococcus lactis expressing human papillomavirus type 16 E6 Oncoprotein vaccine. Mol Ther Methods Clin Dev. 2019;15:40\u201351. https:\/\/doi.org\/10.1016\/j.omtm.2019.08.005.","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"8","key":"98_CR56","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1007\/s00262-012-1259-8","volume":"61","author":"K Barrios","year":"2012","unstructured":"Barrios K, Celis E. TriVax-HPV: an improved peptide-based therapeutic vaccination strategy against human papillomavirus-induced cancers. Cancer Immunol Immunother. 2012;61(8):1307\u201317. https:\/\/doi.org\/10.1007\/s00262-012-1259-8.","journal-title":"Cancer Immunol Immunother"},{"issue":"9014","key":"98_CR57","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1016\/s0140-6736(96)90674-1","volume":"347","author":"LK Borysiewicz","year":"1996","unstructured":"Borysiewicz LK, Fiander A, Nimako M, Man S, Wilkinson GW, Westmoreland D, et al. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet. 1996;347(9014):1523\u20137. https:\/\/doi.org\/10.1016\/s0140-6736(96)90674-1.","journal-title":"Lancet."},{"issue":"12","key":"98_CR58","first-page":"3676","volume":"8","author":"AM Kaufmann","year":"2002","unstructured":"Kaufmann AM, Stern PL, Rankin EM, Sommer H, Nuessler V, Schneider A, et al. Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer. Clin Cancer Res. 2002;8(12):3676\u201385.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"98_CR59","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.ygyno.2019.03.250","volume":"153","author":"DM Harper","year":"2019","unstructured":"Harper DM, Nieminen P, Donders G, Einstein MH, Garcia F, Huh WK, et al. The efficacy and safety of Tipapkinogen Sovacivec therapeutic HPV vaccine in cervical intraepithelial neoplasia grades 2 and 3: randomized controlled phase II trial with 2.5\u00a0years of follow-up. Gynecol Oncol. 2019;153(3):521\u20139. https:\/\/doi.org\/10.1016\/j.ygyno.2019.03.250.","journal-title":"Gynecol Oncol"},{"issue":"7","key":"98_CR60","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1002\/ijc.31166","volume":"142","author":"N \u00c7uburu","year":"2018","unstructured":"\u00c7uburu N, Khan S, Thompson CD, Kim R, Vellinga J, Zahn R, et al. Adenovirus vector-based prime-boost vaccination via heterologous routes induces cervicovaginal CD8(+) T cell responses against HPV16 oncoproteins. Int J Cancer. 2018;142(7):1467\u201379. https:\/\/doi.org\/10.1002\/ijc.31166.","journal-title":"Int J Cancer"},{"issue":"11\u201312","key":"98_CR61","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1016\/s0264-410x(02)00558-3","volume":"21","author":"T Daemen","year":"2003","unstructured":"Daemen T, Riezebos-Brilman A, Bungener L, Regts J, Dontje B, Wilschut J. Eradication of established HPV16-transformed tumours after immunisation with recombinant Semliki Forest virus expressing a fusion protein of E6 and E7. Vaccine. 2003;21(11\u201312):1082\u20138. https:\/\/doi.org\/10.1016\/s0264-410x(02)00558-3.","journal-title":"Vaccine."},{"issue":"1","key":"98_CR62","doi-asserted-by":"publisher","first-page":"1809960","DOI":"10.1080\/2162402x.2020.1809960","volume":"9","author":"S Schmidt","year":"2020","unstructured":"Schmidt S, Bonilla WV, Reiter A, Stemeseder F, Kleissner T, Oeler D, et al. Live-attenuated lymphocytic choriomeningitis virus-based vaccines for active immunotherapy of HPV16-positive cancer. Oncoimmunology. 2020;9(1):1809960. https:\/\/doi.org\/10.1080\/2162402x.2020.1809960.","journal-title":"Oncoimmunology."},{"key":"98_CR63","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.virusres.2016.12.002","volume":"231","author":"A Yang","year":"2017","unstructured":"Yang A, Farmer E, Lin J, Wu TC, Hung CF. The current state of therapeutic and T cell-based vaccines against human papillomaviruses. Virus Res. 2017;231:148\u201365. https:\/\/doi.org\/10.1016\/j.virusres.2016.12.002.","journal-title":"Virus Res"},{"issue":"9","key":"98_CR64","first-page":"3406","volume":"6","author":"L Muderspach","year":"2000","unstructured":"Muderspach L, Wilczynski S, Roman L, Bade L, Felix J, Small LA, et al. A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive. Clin Cancer Res. 2000;6(9):3406\u201316.","journal-title":"Clin Cancer Res"},{"issue":"19","key":"98_CR65","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1056\/NEJMoa0810097","volume":"361","author":"GG Kenter","year":"2009","unstructured":"Kenter GG, Welters MJ, Valentijn AR, Lowik MJ, Berends-van der Meer DM, Vloon AP, et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med. 2009;361(19):1838\u201347. https:\/\/doi.org\/10.1056\/NEJMoa0810097.","journal-title":"N Engl J Med"},{"issue":"9","key":"98_CR66","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1007\/s00262-012-1292-7","volume":"61","author":"PJ de Vos van Steenwijk","year":"2012","unstructured":"de Vos van Steenwijk PJ, Ramwadhdoebe TH, L\u00f6wik MJ, van der Minne CE, Berends-van der Meer DM, Fathers LM, et al. A placebo-controlled randomized HPV16 synthetic long-peptide vaccination study in women with high-grade cervical squamous intraepithelial lesions. Cancer Immunol Immunother. 2012;61(9):1485\u201392. https:\/\/doi.org\/10.1007\/s00262-012-1292-7.","journal-title":"Cancer Immunol Immunother"},{"key":"98_CR67","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/1479-5876-11-88","volume":"11","author":"MI van Poelgeest","year":"2013","unstructured":"van Poelgeest MI, Welters MJ, van Esch EM, Stynenbosch LF, Kerpershoek G, Persijn van Meerten EL, et al. HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial. J Transl Med. 2013;11:88. https:\/\/doi.org\/10.1186\/1479-5876-11-88.","journal-title":"J Transl Med"},{"issue":"2","key":"98_CR68","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s00262-013-1499-2","volume":"63","author":"PJ de Vos van Steenwijk","year":"2014","unstructured":"de Vos van Steenwijk PJ, van Poelgeest MI, Ramwadhdoebe TH, L\u00f6wik MJ, Berends-van der Meer DM, van der Minne CE, et al. The long-term immune response after HPV16 peptide vaccination in women with low-grade pre-malignant disorders of the uterine cervix: a placebo-controlled phase II study. Cancer Immunol Immunother. 2014;63(2):147\u201360. https:\/\/doi.org\/10.1007\/s00262-013-1499-2.","journal-title":"Cancer Immunol Immunother"},{"issue":"334","key":"98_CR69","doi-asserted-by":"publisher","first-page":"334ra52","DOI":"10.1126\/scitranslmed.aad8307","volume":"8","author":"MJ Welters","year":"2016","unstructured":"Welters MJ, van der Sluis TC, van Meir H, Loof NM, van Ham VJ, van Duikeren S, et al. Vaccination during myeloid cell depletion by cancer chemotherapy fosters robust T cell responses. Sci Transl Med. 2016;8(334):334ra52. https:\/\/doi.org\/10.1126\/scitranslmed.aad8307.","journal-title":"Sci Transl Med"},{"key":"98_CR70","doi-asserted-by":"publisher","unstructured":"Melief CJM, Welters MJP, Vergote I, Kroep JR, Kenter GG, Ottevanger PB, et al. Strong vaccine responses during chemotherapy are associated with prolonged cancer survival. Sci Transl Med. 2020;12(535). https:\/\/doi.org\/10.1126\/scitranslmed.aaz8235.","DOI":"10.1126\/scitranslmed.aaz8235"},{"key":"98_CR71","doi-asserted-by":"publisher","unstructured":"Sousa LG, Rajapakshe K, Rodriguez Canales J, Chin RL, Feng L, Wang Q, et al. ISA101 and nivolumab for HPV-16(+) cancer: updated clinical efficacy and immune correlates of response. J Immunother Cancer. 2022;10(2). https:\/\/doi.org\/10.1136\/jitc-2021-004232.","DOI":"10.1136\/jitc-2021-004232"},{"issue":"13","key":"98_CR72","doi-asserted-by":"publisher","first-page":"3238","DOI":"10.1158\/1078-0432.Ccr-16-0085","volume":"22","author":"P Van Damme","year":"2016","unstructured":"Van Damme P, Bouillette-Marussig M, Hens A, De Coster I, Depuydt C, Goubier A, et al. GTL001, a therapeutic vaccine for women infected with human papillomavirus 16 or 18 and Normal cervical cytology: results of a phase I clinical trial. Clin Cancer Res. 2016;22(13):3238\u201348. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-16-0085.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"98_CR73","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.ygyno.2007.04.038","volume":"106","author":"MH Einstein","year":"2007","unstructured":"Einstein MH, Kadish AS, Burk RD, Kim MY, Wadler S, Streicher H, et al. Heat shock fusion protein-based immunotherapy for treatment of cervical intraepithelial neoplasia III. Gynecol Oncol. 2007;106(3):453\u201360. https:\/\/doi.org\/10.1016\/j.ygyno.2007.04.038.","journal-title":"Gynecol Oncol"},{"issue":"22","key":"98_CR74","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.1016\/j.vaccine.2019.04.043","volume":"37","author":"DM Da Silva","year":"2019","unstructured":"Da Silva DM, Skeate JG, Chavez-Juan E, L\u00fchen KP, Wu JM, Wu CM, et al. Therapeutic efficacy of a human papillomavirus type 16 E7 bacterial exotoxin fusion protein adjuvanted with CpG or GPI-0100 in a preclinical mouse model for HPV-associated disease. Vaccine. 2019;37(22):2915\u201324. https:\/\/doi.org\/10.1016\/j.vaccine.2019.04.043.","journal-title":"Vaccine."},{"issue":"5","key":"98_CR75","doi-asserted-by":"publisher","first-page":"e51","DOI":"10.3802\/jgo.2016.27.e51","volume":"27","author":"SJ Lee","year":"2016","unstructured":"Lee SJ, Yang A, Wu TC, Hung CF. Immunotherapy for human papillomavirus-associated disease and cervical cancer: review of clinical and translational research. J Gynecol Oncol. 2016;27(5):e51. https:\/\/doi.org\/10.3802\/jgo.2016.27.e51.","journal-title":"J Gynecol Oncol"},{"issue":"7","key":"98_CR76","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1111\/jog.14276","volume":"46","author":"F Barra","year":"2020","unstructured":"Barra F, Della Corte L, Noberasco G, Foreste V, Riemma G, Di Filippo C, et al. Advances in therapeutic vaccines for treating human papillomavirus-related cervical intraepithelial neoplasia. J Obstet Gynaecol Res. 2020;46(7):989\u20131006. https:\/\/doi.org\/10.1111\/jog.14276.","journal-title":"J Obstet Gynaecol Res"},{"key":"98_CR77","doi-asserted-by":"publisher","unstructured":"Bagarazzi ML, Yan J, Morrow MP, Shen X, Parker RL, Lee JC, et al. Immunotherapy against HPV16\/18 generates potent TH1 and cytotoxic cellular immune responses. Sci Transl Med. 2012;4(155):155ra138. https:\/\/doi.org\/10.1126\/scitranslmed.3004414.","DOI":"10.1126\/scitranslmed.3004414"},{"issue":"10008","key":"98_CR78","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1016\/s0140-6736(15)00239-1","volume":"386","author":"CL Trimble","year":"2015","unstructured":"Trimble CL, Morrow MP, Kraynyak KA, Shen X, Dallas M, Yan J, et al. Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2\/3: a randomised, double-blind, placebo-controlled phase 2b trial. Lancet. 2015;386(10008):2078\u201388. https:\/\/doi.org\/10.1016\/s0140-6736(15)00239-1.","journal-title":"Lancet."},{"key":"98_CR79","doi-asserted-by":"publisher","first-page":"5317","DOI":"10.1038\/ncomms6317","volume":"5","author":"TJ Kim","year":"2014","unstructured":"Kim TJ, Jin HT, Hur SY, Yang HG, Seo YB, Hong SR, et al. Clearance of persistent HPV infection and cervical lesion by therapeutic DNA vaccine in CIN3 patients. Nat Commun. 2014;5:5317. https:\/\/doi.org\/10.1038\/ncomms6317.","journal-title":"Nat Commun"},{"issue":"7","key":"98_CR80","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1158\/1078-0432.Ccr-19-1513","volume":"26","author":"YJ Choi","year":"2020","unstructured":"Choi YJ, Hur SY, Kim TJ, Hong SR, Lee JK, Cho CH, et al. A phase II, prospective, randomized, multicenter, open-label study of GX-188E, an HPV DNA vaccine, in patients with cervical intraepithelial Neoplasia 3. Clin Cancer Res. 2020;26(7):1616\u201323. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-19-1513.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"98_CR81","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.ygyno.2015.11.026","volume":"140","author":"RD Alvarez","year":"2016","unstructured":"Alvarez RD, Huh WK, Bae S, Lamb LS Jr, Conner MG, Boyer J, et al. A pilot study of pNGVL4a-CRT\/E7(detox) for the treatment of patients with HPV16+ cervical intraepithelial neoplasia 2\/3 (CIN2\/3). Gynecol Oncol. 2016;140(2):245\u201352. https:\/\/doi.org\/10.1016\/j.ygyno.2015.11.026.","journal-title":"Gynecol Oncol"},{"issue":"2","key":"98_CR82","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1097\/01.Aog.0000110246.93627.17","volume":"103","author":"F Garcia","year":"2004","unstructured":"Garcia F, Petry KU, Muderspach L, Gold MA, Braly P, Crum CP, et al. ZYC101a for treatment of high-grade cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol. 2004;103(2):317\u201326. https:\/\/doi.org\/10.1097\/01.Aog.0000110246.93627.17.","journal-title":"Obstet Gynecol"},{"issue":"4","key":"98_CR83","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.tim.2018.01.009","volume":"26","author":"C Shih","year":"2018","unstructured":"Shih C, Yang CC, Choijilsuren G, Chang CH, Liou AT. Hepatitis B virus. Trends Microbiol. 2018;26(4):386\u20137. https:\/\/doi.org\/10.1016\/j.tim.2018.01.009.","journal-title":"Trends Microbiol"},{"issue":"1","key":"98_CR84","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1093\/infdis\/jiv748","volume":"214","author":"MG Bruce","year":"2016","unstructured":"Bruce MG, Bruden D, Hurlburt D, Zanis C, Thompson G, Rea L, et al. Antibody levels and protection after hepatitis B vaccine: results of a 30-year follow-up study and response to a booster dose. J Infect Dis. 2016;214(1):16\u201322. https:\/\/doi.org\/10.1093\/infdis\/jiv748.","journal-title":"J Infect Dis"},{"issue":"2","key":"98_CR85","doi-asserted-by":"publisher","first-page":"165","DOI":"10.14218\/jcth.2018.00037","volume":"7","author":"S Das","year":"2019","unstructured":"Das S, Ramakrishnan K, Behera SK, Ganesapandian M, Xavier AS, Selvarajan S. Hepatitis B vaccine and immunoglobulin: key concepts. J Clin Transl Hepatol. 2019;7(2):165\u201371. https:\/\/doi.org\/10.14218\/jcth.2018.00037.","journal-title":"J Clin Transl Hepatol"},{"issue":"7","key":"98_CR86","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1111\/apt.13751","volume":"44","author":"M Vigan\u00f2","year":"2016","unstructured":"Vigan\u00f2 M, Invernizzi F, Grossi G, Lampertico P. Review article: the potential of interferon and nucleos(t)ide analogue combination therapy in chronic hepatitis B infection. Aliment Pharmacol Ther. 2016;44(7):653\u201361. https:\/\/doi.org\/10.1111\/apt.13751.","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"98_CR87","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1053\/j.gastro.2009.03.006","volume":"136","author":"P Marcellin","year":"2009","unstructured":"Marcellin P, Bonino F, Lau GK, Farci P, Yurdaydin C, Piratvisuth T, et al. Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a. Gastroenterology. 2009;136(7):2169\u20132179.e1\u20134. https:\/\/doi.org\/10.1053\/j.gastro.2009.03.006.","journal-title":"Gastroenterology."},{"issue":"3","key":"98_CR88","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1002\/hep.20128","volume":"39","author":"M van Zonneveld","year":"2004","unstructured":"van Zonneveld M, Honkoop P, Hansen BE, Niesters HG, Darwish Murad S, de Man RA, et al. Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. Hepatology. 2004;39(3):804\u201310. https:\/\/doi.org\/10.1002\/hep.20128.","journal-title":"Hepatology."},{"issue":"8","key":"98_CR89","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.4254\/wjh.v7.i8.1064","volume":"7","author":"I Rapti","year":"2015","unstructured":"Rapti I, Hadziyannis S. Risk for hepatocellular carcinoma in the course of chronic hepatitis B virus infection and the protective effect of therapy with nucleos(t)ide analogues. World J Hepatol. 2015;7(8):1064\u201373. https:\/\/doi.org\/10.4254\/wjh.v7.i8.1064.","journal-title":"World J Hepatol"},{"issue":"8","key":"98_CR90","doi-asserted-by":"publisher","first-page":"4215","DOI":"10.1128\/jvi.02844-06","volume":"81","author":"C Boni","year":"2007","unstructured":"Boni C, Fisicaro P, Valdatta C, Amadei B, Di Vincenzo P, Giuberti T, et al. Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J Virol. 2007;81(8):4215\u201325. https:\/\/doi.org\/10.1128\/jvi.02844-06.","journal-title":"J Virol"},{"issue":"9","key":"98_CR91","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1084\/jem.20011723","volume":"195","author":"S Reignat","year":"2002","unstructured":"Reignat S, Webster GJ, Brown D, Ogg GS, King A, Seneviratne SL, et al. Escaping high viral load exhaustion: CD8 cells with altered tetramer binding in chronic hepatitis B virus infection. J Exp Med. 2002;195(9):1089\u2013101. https:\/\/doi.org\/10.1084\/jem.20011723.","journal-title":"J Exp Med"},{"issue":"10","key":"98_CR92","doi-asserted-by":"publisher","first-page":"4573","DOI":"10.1172\/jci121957","volume":"128","author":"L Salimzadeh","year":"2018","unstructured":"Salimzadeh L, Le Bert N, Dutertre CA, Gill US, Newell EW, Frey C, et al. PD-1 blockade partially recovers dysfunctional virus-specific B cells in chronic hepatitis B infection. J Clin Invest. 2018;128(10):4573\u201387. https:\/\/doi.org\/10.1172\/jci121957.","journal-title":"J Clin Invest"},{"issue":"1","key":"98_CR93","doi-asserted-by":"publisher","first-page":"e6","DOI":"10.4110\/in.2021.21.e6","volume":"21","author":"J Chang","year":"2021","unstructured":"Chang J. Adenovirus vectors: excellent tools for vaccine development. Immune Netw. 2021;21(1):e6. https:\/\/doi.org\/10.4110\/in.2021.21.e6.","journal-title":"Immune Netw"},{"issue":"12","key":"98_CR94","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1136\/gutjnl-2014-308041","volume":"64","author":"P Martin","year":"2015","unstructured":"Martin P, Dubois C, Jacquier E, Dion S, Mancini-Bourgine M, Godon O, et al. TG1050, an immunotherapeutic to treat chronic hepatitis B, induces robust T cells and exerts an antiviral effect in HBV-persistent mice. Gut. 2015;64(12):1961\u201371. https:\/\/doi.org\/10.1136\/gutjnl-2014-308041.","journal-title":"Gut."},{"issue":"2","key":"98_CR95","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1080\/21645515.2019.1651141","volume":"16","author":"F Zoulim","year":"2020","unstructured":"Zoulim F, Fournier C, Habersetzer F, Sprinzl M, Pol S, Coffin CS, et al. Safety and immunogenicity of the therapeutic vaccine TG1050 in chronic hepatitis B patients: a phase 1b placebo-controlled trial. Hum Vaccin Immunother. 2020;16(2):388\u201399. https:\/\/doi.org\/10.1080\/21645515.2019.1651141.","journal-title":"Hum Vaccin Immunother"},{"key":"98_CR96","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.omtn.2018.05.006","volume":"12","author":"M Schiwon","year":"2018","unstructured":"Schiwon M, Ehrke-Schulz E, Oswald A, Bergmann T, Michler T, Protzer U, et al. One-vector system for multiplexed CRISPR\/Cas9 against hepatitis B virus cccDNA utilizing high-capacity adenoviral vectors. Mol Ther Nucleic Acids. 2018;12:242\u201353. https:\/\/doi.org\/10.1016\/j.omtn.2018.05.006.","journal-title":"Mol Ther Nucleic Acids"},{"key":"98_CR97","doi-asserted-by":"publisher","unstructured":"Kato Y, Tabata H, Sato K, Nakamura M, Saito I, Nakanishi T. Adenovirus vectors expressing eight multiplex guide RNAs of CRISPR\/Cas9 efficiently disrupted diverse hepatitis B virus gene derived from heterogeneous patient. Int J Mol Sci. 2021;22(19). https:\/\/doi.org\/10.3390\/ijms221910570.","DOI":"10.3390\/ijms221910570"},{"issue":"17\u201318","key":"98_CR98","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1016\/s0264-410x(02)00771-5","volume":"21","author":"VS Moorthy","year":"2003","unstructured":"Moorthy VS, McConkey S, Roberts M, Gothard P, Arulanantham N, Degano P, et al. Safety of DNA and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers. Vaccine. 2003;21(17\u201318):1995\u20132002. https:\/\/doi.org\/10.1016\/s0264-410x(02)00771-5.","journal-title":"Vaccine."},{"key":"98_CR99","doi-asserted-by":"publisher","unstructured":"Chinnakannan SK, Cargill TN, Donnison TA, Ansari MA, Sebastian S, Lee LN, et al. The design and development of a multi-HBV antigen encoded in chimpanzee adenoviral and modified Vaccinia Ankara viral vectors; a novel therapeutic vaccine strategy against HBV. Vaccines (Basel). 2020;8(2). https:\/\/doi.org\/10.3390\/vaccines8020184.","DOI":"10.3390\/vaccines8020184"},{"key":"98_CR100","doi-asserted-by":"publisher","unstructured":"Boni C, Barili V, Acerbi G, Rossi M, Vecchi A, Laccabue D, et al. HBV immune-therapy: from molecular mechanisms to clinical applications. Int J Mol Sci. 2019;20(11). https:\/\/doi.org\/10.3390\/ijms20112754.","DOI":"10.3390\/ijms20112754"},{"issue":"39","key":"98_CR101","doi-asserted-by":"publisher","first-page":"4925","DOI":"10.1016\/j.vaccine.2014.07.027","volume":"32","author":"A Gaggar","year":"2014","unstructured":"Gaggar A, Coeshott C, Apelian D, Rodell T, Armstrong BR, Shen G, et al. Safety, tolerability and immunogenicity of GS-4774, a hepatitis B virus-specific therapeutic vaccine, in healthy subjects: a randomized study. Vaccine. 2014;32(39):4925\u201331. https:\/\/doi.org\/10.1016\/j.vaccine.2014.07.027.","journal-title":"Vaccine."},{"issue":"5","key":"98_CR102","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1038\/87974","volume":"7","author":"AC Stubbs","year":"2001","unstructured":"Stubbs AC, Martin KS, Coeshott C, Skaates SV, Kuritzkes DR, Bellgrau D, et al. Whole recombinant yeast vaccine activates dendritic cells and elicits protective cell-mediated immunity. Nat Med. 2001;7(5):625\u20139. https:\/\/doi.org\/10.1038\/87974.","journal-title":"Nat Med"},{"issue":"1","key":"98_CR103","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1053\/j.gastro.2019.03.044","volume":"157","author":"C Boni","year":"2019","unstructured":"Boni C, Janssen HLA, Rossi M, Yoon SK, Vecchi A, Barili V, et al. Combined GS-4774 and Tenofovir therapy can improve HBV-specific T-cell responses in patients with chronic hepatitis. Gastroenterology. 2019;157(1):227\u2013241.e7. https:\/\/doi.org\/10.1053\/j.gastro.2019.03.044.","journal-title":"Gastroenterology."},{"issue":"5","key":"98_CR104","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1111\/j.0818-9641.2004.01278.x","volume":"82","author":"JC Aguilar","year":"2004","unstructured":"Aguilar JC, Lobaina Y, Muzio V, Garc\u00eda D, Pent\u00f3n E, Iglesias E, et al. Development of a nasal vaccine for chronic hepatitis B infection that uses the ability of hepatitis B core antigen to stimulate a strong Th1 response against hepatitis B surface antigen. Immunol Cell Biol. 2004;82(5):539\u201346. https:\/\/doi.org\/10.1111\/j.0818-9641.2004.01278.x.","journal-title":"Immunol Cell Biol"},{"issue":"5","key":"98_CR105","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.ijid.2006.09.010","volume":"11","author":"AA Betancourt","year":"2007","unstructured":"Betancourt AA, Delgado CA, Est\u00e9vez ZC, Mart\u00ednez JC, R\u00edos GV, Aureoles-Rosell\u00f3 SR, et al. Phase I clinical trial in healthy adults of a nasal vaccine candidate containing recombinant hepatitis B surface and core antigens. Int J Infect Dis. 2007;11(5):394\u2013401. https:\/\/doi.org\/10.1016\/j.ijid.2006.09.010.","journal-title":"Int J Infect Dis"},{"issue":"8","key":"98_CR106","doi-asserted-by":"publisher","first-page":"e0201236","DOI":"10.1371\/journal.pone.0201236","volume":"13","author":"M Al Mahtab","year":"2018","unstructured":"Al Mahtab M, Akbar SMF, Aguilar JC, Guillen G, Penton E, Tuero A, et al. Treatment of chronic hepatitis B na\u00efve patients with a therapeutic vaccine containing HBs and HBc antigens (a randomized, open and treatment controlled phase III clinical trial). PLoS One. 2018;13(8):e0201236. https:\/\/doi.org\/10.1371\/journal.pone.0201236.","journal-title":"PLoS One"},{"issue":"11","key":"98_CR107","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1038\/cgt.2012.61","volume":"19","author":"N Obeng-Adjei","year":"2012","unstructured":"Obeng-Adjei N, Choo DK, Saini J, Yan J, Pankhong P, Parikh A, et al. Synthetic DNA immunogen encoding hepatitis B core antigen drives immune response in liver. Cancer Gene Ther. 2012;19(11):779\u201387. https:\/\/doi.org\/10.1038\/cgt.2012.61.","journal-title":"Cancer Gene Ther"},{"issue":"12","key":"98_CR108","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1038\/cgt.2013.65","volume":"20","author":"N Obeng-Adjei","year":"2013","unstructured":"Obeng-Adjei N, Hutnick NA, Yan J, Chu JS, Myles DJ, Morrow MP, et al. DNA vaccine cocktail expressing genotype a and C HBV surface and consensus core antigens generates robust cytotoxic and antibody responses in mice and rhesus macaques. Cancer Gene Ther. 2013;20(12):652\u201362. https:\/\/doi.org\/10.1038\/cgt.2013.65.","journal-title":"Cancer Gene Ther"},{"issue":"14","key":"98_CR109","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1038\/sj.gt.3302751","volume":"13","author":"SH Yang","year":"2006","unstructured":"Yang SH, Lee CG, Park SH, Im SJ, Kim YM, Son JM, et al. Correlation of antiviral T-cell responses with suppression of viral rebound in chronic hepatitis B carriers: a proof-of-concept study. Gene Ther. 2006;13(14):1110\u20137. https:\/\/doi.org\/10.1038\/sj.gt.3302751.","journal-title":"Gene Ther"},{"issue":"3","key":"98_CR110","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1111\/liv.12530","volume":"35","author":"SK Yoon","year":"2015","unstructured":"Yoon SK, Seo YB, Im SJ, Bae SH, Song MJ, You CR, et al. Safety and immunogenicity of therapeutic DNA vaccine with antiviral drug in chronic HBV patients and its immunogenicity in mice. Liver Int. 2015;35(3):805\u201315. https:\/\/doi.org\/10.1111\/liv.12530.","journal-title":"Liver Int"},{"key":"98_CR111","doi-asserted-by":"publisher","unstructured":"Mu Z, Haynes BF, Cain DW. HIV mRNA vaccines-Progress and future paths. Vaccines (Basel). 2021;9(2). https:\/\/doi.org\/10.3390\/vaccines9020134.","DOI":"10.3390\/vaccines9020134"},{"key":"98_CR112","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1146\/annurev-med-052912-123749","volume":"66","author":"JH Kim","year":"2015","unstructured":"Kim JH, Excler JL, Michael NL. Lessons from the RV144 Thai phase III HIV-1 vaccine trial and the search for correlates of protection. Annu Rev Med. 2015;66:423\u201337. https:\/\/doi.org\/10.1146\/annurev-med-052912-123749.","journal-title":"Annu Rev Med"},{"issue":"8","key":"98_CR113","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1080\/14760584.2022.2080658","volume":"21","author":"J Jonny","year":"2022","unstructured":"Jonny J, Putranto TA, Sitepu EC, Irfon R. Dendritic cell vaccine as a potential strategy to end the COVID-19 pandemic. Why should it be ex vivo? Expert Rev Vaccines. 2022;21(8):1111\u201320. https:\/\/doi.org\/10.1080\/14760584.2022.2080658.","journal-title":"Expert Rev Vaccines"},{"issue":"9","key":"98_CR114","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1093\/infdis\/jiv582","volume":"213","author":"BJ Macatangay","year":"2016","unstructured":"Macatangay BJ, Riddler SA, Wheeler ND, Spindler J, Lawani M, Hong F, et al. Therapeutic vaccination with dendritic cells loaded with autologous HIV type 1-infected apoptotic cells. J Infect Dis. 2016;213(9):1400\u20139. https:\/\/doi.org\/10.1093\/infdis\/jiv582.","journal-title":"J Infect Dis"},{"issue":"1","key":"98_CR115","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1089\/aid.2017.0071","volume":"34","author":"CL Gay","year":"2018","unstructured":"Gay CL, DeBenedette MA, Tcherepanova IY, Gamble A, Lewis WE, Cope AB, et al. Immunogenicity of AGS-004 dendritic cell therapy in patients treated during acute HIV infection. AIDS Res Hum Retrovir. 2018;34(1):111\u201322. https:\/\/doi.org\/10.1089\/aid.2017.0071.","journal-title":"AIDS Res Hum Retrovir"},{"issue":"1","key":"98_CR116","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1097\/qai.0000000000000926","volume":"72","author":"JM Jacobson","year":"2016","unstructured":"Jacobson JM, Routy JP, Welles S, DeBenedette M, Tcherepanova I, Angel JB, et al. Dendritic cell immunotherapy for HIV-1 infection using autologous HIV-1 RNA: a randomized, double-blind, placebo-controlled clinical trial. J Acquir Immune Defic Syndr. 2016;72(1):31\u20138. https:\/\/doi.org\/10.1097\/qai.0000000000000926.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"17","key":"98_CR117","doi-asserted-by":"publisher","first-page":"2533","DOI":"10.1097\/qad.0000000000002026","volume":"32","author":"L Leal","year":"2018","unstructured":"Leal L, Guardo AC, Mor\u00f3n-L\u00f3pez S, Salgado M, Mothe B, Heirman C, et al. Phase I clinical trial of an intranodally administered mRNA-based therapeutic vaccine against HIV-1 infection. Aids. 2018;32(17):2533\u201345. https:\/\/doi.org\/10.1097\/qad.0000000000002026.","journal-title":"Aids."},{"issue":"1","key":"98_CR118","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1186\/s13063-019-3409-1","volume":"20","author":"W de Jong","year":"2019","unstructured":"de Jong W, Aerts J, Allard S, Brander C, Buyze J, Florence E, et al. iHIVARNA phase IIa, a randomized, placebo-controlled, double-blinded trial to evaluate the safety and immunogenicity of iHIVARNA-01 in chronically HIV-infected patients under stable combined antiretroviral therapy. Trials. 2019;20(1):361. https:\/\/doi.org\/10.1186\/s13063-019-3409-1.","journal-title":"Trials."},{"issue":"1","key":"98_CR119","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41541-022-00503-y","volume":"7","author":"T Travieso","year":"2022","unstructured":"Travieso T, Li J, Mahesh S, Mello JDFRE, Blasi M. The use of viral vectors in vaccine development. npj Vaccines. 2022;7(1):75. https:\/\/doi.org\/10.1038\/s41541-022-00503-y.","journal-title":"npj Vaccines"},{"issue":"1","key":"98_CR120","doi-asserted-by":"publisher","first-page":"21171","DOI":"10.7448\/ias.20.1.21171","volume":"20","author":"G Hancock","year":"2017","unstructured":"Hancock G, Mor\u00f3n-L\u00f3pez S, Kopycinski J, Puertas MC, Giannoulatou E, Rose A, et al. Evaluation of the immunogenicity and impact on the latent HIV-1 reservoir of a conserved region vaccine, MVA.HIVconsv, in antiretroviral therapy-treated subjects. J Int AIDS Soc. 2017;20(1):21171. https:\/\/doi.org\/10.7448\/ias.20.1.21171.","journal-title":"J Int AIDS Soc"},{"issue":"19","key":"98_CR121","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1016\/j.vaccine.2016.03.021","volume":"34","author":"FY Tung","year":"2016","unstructured":"Tung FY, Tung JK, Pallikkuth S, Pahwa S, Fischl MA. A therapeutic HIV-1 vaccine enhances anti-HIV-1 immune responses in patients under highly active antiretroviral therapy. Vaccine. 2016;34(19):2225\u201332. https:\/\/doi.org\/10.1016\/j.vaccine.2016.03.021.","journal-title":"Vaccine."},{"issue":"8","key":"98_CR122","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1515\/hsz-2017-0118","volume":"398","author":"T Tu","year":"2017","unstructured":"Tu T, Buhler S, Bartenschlager R. Chronic viral hepatitis and its association with liver cancer. Biol Chem. 2017;398(8):817\u201337. https:\/\/doi.org\/10.1515\/hsz-2017-0118.","journal-title":"Biol Chem"},{"key":"98_CR123","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.antiviral.2014.11.009","volume":"114","author":"L Holz","year":"2015","unstructured":"Holz L, Rehermann B. T cell responses in hepatitis C virus infection: historical overview and goals for future research. Antivir Res. 2015;114:96\u2013105. https:\/\/doi.org\/10.1016\/j.antiviral.2014.11.009.","journal-title":"Antivir Res"},{"key":"98_CR124","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.pharmthera.2017.10.009","volume":"183","author":"U Spengler","year":"2018","unstructured":"Spengler U. Direct antiviral agents (DAAs) - a new age in the treatment of hepatitis C virus infection. Pharmacol Ther. 2018;183:118\u201326. https:\/\/doi.org\/10.1016\/j.pharmthera.2017.10.009.","journal-title":"Pharmacol Ther"},{"issue":"3","key":"98_CR125","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1053\/j.gastro.2004.06.015","volume":"127","author":"GM Lauer","year":"2004","unstructured":"Lauer GM, Barnes E, Lucas M, Timm J, Ouchi K, Kim AY, et al. High resolution analysis of cellular immune responses in resolved and persistent hepatitis C virus infection. Gastroenterology. 2004;127(3):924\u201336. https:\/\/doi.org\/10.1053\/j.gastro.2004.06.015.","journal-title":"Gastroenterology."},{"issue":"42","key":"98_CR126","doi-asserted-by":"publisher","first-page":"7429","DOI":"10.1016\/j.vaccine.2007.08.005","volume":"25","author":"S Yutani","year":"2007","unstructured":"Yutani S, Yamada A, Yoshida K, Takao Y, Tamura M, Komatsu N, et al. Phase I clinical study of a personalized peptide vaccination for patients infected with hepatitis C virus (HCV) 1b who failed to respond to interferon-based therapy. Vaccine. 2007;25(42):7429\u201335. https:\/\/doi.org\/10.1016\/j.vaccine.2007.08.005.","journal-title":"Vaccine."},{"issue":"5","key":"98_CR127","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1053\/j.gastro.2008.02.058","volume":"134","author":"CS Klade","year":"2008","unstructured":"Klade CS, Wedemeyer H, Berg T, Hinrichsen H, Cholewinska G, Zeuzem S, et al. Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41. Gastroenterology. 2008;134(5):1385\u201395. https:\/\/doi.org\/10.1053\/j.gastro.2008.02.058.","journal-title":"Gastroenterology."},{"issue":"12","key":"98_CR128","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.1016\/j.vaccine.2009.12.072","volume":"28","author":"C Firbas","year":"2010","unstructured":"Firbas C, Boehm T, Buerger V, Schuller E, Sabarth N, Jilma B, et al. Immunogenicity and safety of different injection routes and schedules of IC41, a hepatitis C virus (HCV) peptide vaccine. Vaccine. 2010;28(12):2397\u2013407. https:\/\/doi.org\/10.1016\/j.vaccine.2009.12.072.","journal-title":"Vaccine."},{"issue":"10","key":"98_CR129","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1111\/j.1349-7006.2009.01256.x","volume":"100","author":"S Yutani","year":"2009","unstructured":"Yutani S, Komatsu N, Shichijo S, Yoshida K, Takedatsu H, Itou M, et al. Phase I clinical study of a peptide vaccination for hepatitis C virus-infected patients with different human leukocyte antigen-class I-A alleles. Cancer Sci. 2009;100(10):1935\u201342. https:\/\/doi.org\/10.1111\/j.1349-7006.2009.01256.x.","journal-title":"Cancer Sci"},{"issue":"4","key":"98_CR130","first-page":"456","volume":"11","author":"F Habersetzer","year":"2009","unstructured":"Habersetzer F, Baumert TF, Stoll-Keller F. GI-5005, a yeast vector vaccine expressing an NS3-core fusion protein for chronic HCV infection. Curr Opin Mol Ther. 2009;11(4):456\u201362.","journal-title":"Curr Opin Mol Ther"},{"issue":"8","key":"98_CR131","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1016\/j.vaccine.2006.10.035","volume":"25","author":"AA Haller","year":"2007","unstructured":"Haller AA, Lauer GM, King TH, Kemmler C, Fiolkoski V, Lu Y, et al. Whole recombinant yeast-based immunotherapy induces potent T cell responses targeting HCV NS3 and Core proteins. Vaccine. 2007;25(8):1452\u201363. https:\/\/doi.org\/10.1016\/j.vaccine.2006.10.035.","journal-title":"Vaccine."},{"issue":"1","key":"98_CR132","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.antiviral.2012.07.006","volume":"96","author":"PP Ip","year":"2012","unstructured":"Ip PP, Nijman HW, Wilschut J, Daemen T. Therapeutic vaccination against chronic hepatitis C virus infection. Antivir Res. 2012;96(1):36\u201350. https:\/\/doi.org\/10.1016\/j.antiviral.2012.07.006.","journal-title":"Antivir Res"},{"issue":"1","key":"98_CR133","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1186\/s12985-021-01716-8","volume":"18","author":"A Shayeghpour","year":"2021","unstructured":"Shayeghpour A, Kianfar R, Hosseini P, Ajorloo M, Aghajanian S, Hedayat Yaghoobi M, et al. Hepatitis C virus DNA vaccines: a systematic review. Virol J. 2021;18(1):248. https:\/\/doi.org\/10.1186\/s12985-021-01716-8.","journal-title":"Virol J"},{"issue":"3","key":"98_CR134","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1111\/j.1365-2893.2008.01058.x","volume":"16","author":"L Alvarez-Lajonchere","year":"2009","unstructured":"Alvarez-Lajonchere L, Shoukry NH, Gra B, Amador-Canizares Y, Helle F, Bedard N, et al. Immunogenicity of CIGB-230, a therapeutic DNA vaccine preparation, in HCV-chronically infected individuals in a phase I clinical trial. J Viral Hepat. 2009;16(3):156\u201367. https:\/\/doi.org\/10.1111\/j.1365-2893.2008.01058.x.","journal-title":"J Viral Hepat"},{"issue":"1","key":"98_CR135","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1002\/jgm.1407","volume":"12","author":"M Castellanos","year":"2010","unstructured":"Castellanos M, Cinza Z, Dorta Z, Veliz G, Vega H, Lorenzo I, et al. Immunization with a DNA vaccine candidate in chronic hepatitis C patients is safe, well tolerated and does not impair immune response induction after anti-hepatitis B vaccination. J Gene Med. 2010;12(1):107\u201316. https:\/\/doi.org\/10.1002\/jgm.1407.","journal-title":"J Gene Med"},{"issue":"12","key":"98_CR136","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1086\/498218","volume":"192","author":"G Ahlen","year":"2005","unstructured":"Ahlen G, Nystrom J, Pult I, Frelin L, Hultgren C, Sallberg M. In vivo clearance of hepatitis C virus nonstructural 3\/4A-expressing hepatocytes by DNA vaccine-primed cytotoxic T lymphocytes. J Infect Dis. 2005;192(12):2112\u20136. https:\/\/doi.org\/10.1086\/498218.","journal-title":"J Infect Dis"},{"issue":"6","key":"98_CR137","doi-asserted-by":"publisher","first-page":"e98877","DOI":"10.1371\/journal.pone.0098877","volume":"9","author":"SL Ratnoglik","year":"2014","unstructured":"Ratnoglik SL, Jiang DP, Aoki C, Sudarmono P, Shoji I, Deng L, et al. Induction of cell-mediated immune responses in mice by DNA vaccines that express hepatitis C virus NS3 mutants lacking serine protease and NTPase\/RNA helicase activities. PLoS One. 2014;9(6):e98877. https:\/\/doi.org\/10.1371\/journal.pone.0098877.","journal-title":"PLoS One"},{"issue":"5","key":"98_CR138","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1111\/j.1365-2893.2011.01451.x","volume":"18","author":"K Morikawa","year":"2011","unstructured":"Morikawa K, Lange CM, Gouttenoire J, Meylan E, Brass V, Penin F, et al. Nonstructural protein 3-4A: the Swiss army knife of hepatitis C virus. J Viral Hepat. 2011;18(5):305\u201315. https:\/\/doi.org\/10.1111\/j.1365-2893.2011.01451.x.","journal-title":"J Viral Hepat"},{"issue":"115","key":"98_CR139","doi-asserted-by":"publisher","first-page":"115ra2","DOI":"10.1126\/scitranslmed.3002925","volume":"4","author":"S Colloca","year":"2012","unstructured":"Colloca S, Barnes E, Folgori A, Ammendola V, Capone S, Cirillo A, et al. Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species. Sci Transl Med. 2012;4(115):115ra2. https:\/\/doi.org\/10.1126\/scitranslmed.3002925.","journal-title":"Sci Transl Med"},{"issue":"2","key":"98_CR140","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1038\/nm1353","volume":"12","author":"A Folgori","year":"2006","unstructured":"Folgori A, Capone S, Ruggeri L, Meola A, Sporeno E, Ercole BB, et al. A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees. Nat Med. 2006;12(2):190\u20137. https:\/\/doi.org\/10.1038\/nm1353.","journal-title":"Nat Med"},{"issue":"42","key":"98_CR141","doi-asserted-by":"publisher","first-page":"7339","DOI":"10.1016\/j.vaccine.2007.08.020","volume":"25","author":"A Fournillier","year":"2007","unstructured":"Fournillier A, Gerossier E, Evlashev A, Schmitt D, Simon B, Chatel L, et al. An accelerated vaccine schedule with a poly-antigenic hepatitis C virus MVA-based candidate vaccine induces potent, long lasting and in vivo cross-reactive T cell responses. Vaccine. 2007;25(42):7339\u201353. https:\/\/doi.org\/10.1016\/j.vaccine.2007.08.020.","journal-title":"Vaccine."},{"issue":"4","key":"98_CR142","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.jhep.2010.05.007","volume":"53","author":"EJ Gowans","year":"2010","unstructured":"Gowans EJ, Roberts S, Jones K, Dinatale I, Latour PA, Chua B, et al. A phase I clinical trial of dendritic cell immunotherapy in HCV-infected individuals. J Hepatol. 2010;53(4):599\u2013607. https:\/\/doi.org\/10.1016\/j.jhep.2010.05.007.","journal-title":"J Hepatol"},{"key":"98_CR143","doi-asserted-by":"publisher","first-page":"112527","DOI":"10.1016\/j.biopha.2021.112527","volume":"146","author":"MR Zinatizadeh","year":"2022","unstructured":"Zinatizadeh MR, Zarandi PK, Zinatizadeh M, Yousefi MH, Amani J, Rezaei N. Efficacy of mRNA, adenoviral vector, and perfusion protein COVID-19 vaccines. Biomed Pharmacother. 2022;146:112527. https:\/\/doi.org\/10.1016\/j.biopha.2021.112527.","journal-title":"Biomed Pharmacother"},{"issue":"7","key":"98_CR144","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1056\/NEJMoa2108891","volume":"385","author":"J Lopez Bernal","year":"2021","unstructured":"Lopez Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, et al. Effectiveness of Covid-19 vaccines against the B.1.617.2 (Delta) variant. N Engl J Med. 2021;385(7):585\u201394. https:\/\/doi.org\/10.1056\/NEJMoa2108891.","journal-title":"N Engl J Med"},{"issue":"1","key":"98_CR145","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/s41577-021-00662-4","volume":"22","author":"M Lipsitch","year":"2022","unstructured":"Lipsitch M, Krammer F, Regev-Yochay G, Lustig Y, Balicer RD. SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes and impact. Nat Rev Immunol. 2022;22(1):57\u201365. https:\/\/doi.org\/10.1038\/s41577-021-00662-4.","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"98_CR146","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/s1473-3099(22)00143-8","volume":"22","author":"P Nordstr\u00f6m","year":"2022","unstructured":"Nordstr\u00f6m P, Ballin M, Nordstr\u00f6m A. Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: a retrospective, total population cohort study in Sweden. Lancet Infect Dis. 2022;22(6):781\u201390. https:\/\/doi.org\/10.1016\/s1473-3099(22)00143-8.","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"98_CR147","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/s10875-021-01158-5","volume":"42","author":"RE Bradley","year":"2022","unstructured":"Bradley RE, Ponsford MJ, Scurr MJ, Godkin A, Jolles S. Persistent COVID-19 infection in Wiskott-Aldrich syndrome cleared following therapeutic vaccination: a case report. J Clin Immunol. 2022;42(1):32\u20135. https:\/\/doi.org\/10.1007\/s10875-021-01158-5.","journal-title":"J Clin Immunol"},{"issue":"6","key":"98_CR148","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/s1473-3099(22)00140-2","volume":"22","author":"T Cerqueira-Silva","year":"2022","unstructured":"Cerqueira-Silva T, Andrews JR, Boaventura VS, Ranzani OT, de Ara\u00fajo OV, Paix\u00e3o ES, et al. Effectiveness of CoronaVac, ChAdOx1 nCoV-19, BNT162b2, and Ad26.COV2.S among individuals with previous SARS-CoV-2 infection in Brazil: a test-negative, case-control study. Lancet Infect Dis. 2022;22(6):791\u2013801. https:\/\/doi.org\/10.1016\/s1473-3099(22)00140-2.","journal-title":"Lancet Infect Dis"},{"key":"98_CR149","doi-asserted-by":"publisher","unstructured":"Kikuchi K, Nangaku M, Ryuzaki M, Yamakawa T, Yoshihiro O, Hanafusa N, et al. Effectiveness of SARS-CoV-2 vaccines on hemodialysis patients in Japan: a nationwide cohort study. Ther Apher Dial. 2022. https:\/\/doi.org\/10.1111\/1744-9987.13887.","DOI":"10.1111\/1744-9987.13887"},{"key":"98_CR150","doi-asserted-by":"publisher","first-page":"E62","DOI":"10.5888\/pcd11.130389","volume":"11","author":"BW Ward","year":"2014","unstructured":"Ward BW, Schiller JS, Goodman RA. Multiple chronic conditions among US adults: a 2012 update. Prev Chronic Dis. 2014;11:E62. https:\/\/doi.org\/10.5888\/pcd11.130389.","journal-title":"Prev Chronic Dis"},{"issue":"3","key":"98_CR151","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/nri.2017.131","volume":"18","author":"Z Hu","year":"2018","unstructured":"Hu Z, Ott PA, Wu CJ. Towards personalized, tumour-specific, therapeutic vaccines for cancer. Nat Rev Immunol. 2018;18(3):168\u201382. https:\/\/doi.org\/10.1038\/nri.2017.131.","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"98_CR152","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1042\/cs20030381","volume":"107","author":"MJ Brown","year":"2004","unstructured":"Brown MJ, Coltart J, Gunewardena K, Ritter JM, Auton TR, Glover JF. Randomized double-blind placebo-controlled study of an angiotensin immunotherapeutic vaccine (PMD3117) in hypertensive subjects. Clin Sci (Lond). 2004;107(2):167\u201373. https:\/\/doi.org\/10.1042\/cs20030381.","journal-title":"Clin Sci (Lond)"},{"issue":"1","key":"98_CR153","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1097\/HJH.0b013e32800ff5d6","volume":"25","author":"PM Amb\u00fchl","year":"2007","unstructured":"Amb\u00fchl PM, Tissot AC, Fulurija A, Maurer P, Nussberger J, Sabat R, et al. A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity. J Hypertens. 2007;25(1):63\u201372. https:\/\/doi.org\/10.1097\/HJH.0b013e32800ff5d6.","journal-title":"J Hypertens"},{"issue":"4","key":"98_CR154","first-page":"619","volume":"139","author":"LD Li","year":"2014","unstructured":"Li LD, Tian M, Liao YH, Zhou ZH, Wei F, Zhu F, et al. Effect of active immunization against angiotensin II type 1 (AT1) receptor on hypertension & arterial remodelling in spontaneously hypertensive rats (SHR). Indian J Med Res. 2014;139(4):619\u201324.","journal-title":"Indian J Med Res"},{"issue":"2","key":"98_CR155","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1161\/hypertensionaha.112.201020","volume":"61","author":"X Chen","year":"2013","unstructured":"Chen X, Qiu Z, Yang S, Ding D, Chen F, Zhou Y, et al. Effectiveness and safety of a therapeutic vaccine against angiotensin II receptor type 1 in hypertensive animals. Hypertension. 2013;61(2):408\u201316. https:\/\/doi.org\/10.1161\/hypertensionaha.112.201020.","journal-title":"Hypertension."},{"issue":"1","key":"98_CR156","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/s41440-021-00755-6","volume":"45","author":"H Nakagami","year":"2022","unstructured":"Nakagami H, Ishihama T, Daikyoji Y, Sasakura C, Yamada E, Morishita R. Brief report on a phase I\/IIa study to assess the safety, tolerability, and immune response of AGMG0201 in patients with essential hypertension. Hypertens Res. 2022;45(1):61\u20135. https:\/\/doi.org\/10.1038\/s41440-021-00755-6.","journal-title":"Hypertens Res"},{"issue":"35","key":"98_CR157","doi-asserted-by":"publisher","first-page":"4920","DOI":"10.1016\/j.vaccine.2019.07.044","volume":"37","author":"B Zhao","year":"2019","unstructured":"Zhao B, Marciniuk K, Gibbs E, Yousefi M, Napper S, Cashman NR. Therapeutic vaccines for amyotrophic lateral sclerosis directed against disease specific epitopes of superoxide dismutase 1. Vaccine. 2019;37(35):4920\u20137. https:\/\/doi.org\/10.1016\/j.vaccine.2019.07.044.","journal-title":"Vaccine."},{"issue":"13","key":"98_CR158","doi-asserted-by":"publisher","first-page":"E1256","DOI":"10.1073\/pnas.1322009111","volume":"111","author":"Z Pang","year":"2014","unstructured":"Pang Z, Nakagami H, Osako MK, Koriyama H, Nakagami F, Tomioka H, et al. Therapeutic vaccine against DPP4 improves glucose metabolism in mice. Proc Natl Acad Sci U S A. 2014;111(13):E1256\u201363. https:\/\/doi.org\/10.1073\/pnas.1322009111.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"98_CR159","doi-asserted-by":"publisher","first-page":"12534","DOI":"10.1038\/s41598-017-13069-w","volume":"7","author":"Y Pan","year":"2017","unstructured":"Pan Y, Zhou Y, Wu H, Chen X, Hu X, Zhang H, et al. A therapeutic peptide vaccine against PCSK9. Sci Rep. 2017;7(1):12534. https:\/\/doi.org\/10.1038\/s41598-017-13069-w.","journal-title":"Sci Rep"},{"issue":"2","key":"98_CR160","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.ymthe.2020.09.038","volume":"29","author":"CS Shemesh","year":"2021","unstructured":"Shemesh CS, Hsu JC, Hosseini I, Shen BQ, Rotte A, Twomey P, et al. Personalized cancer vaccines: clinical landscape, challenges, and opportunities. Mol Ther. 2021;29(2):555\u201370. https:\/\/doi.org\/10.1016\/j.ymthe.2020.09.038.","journal-title":"Mol Ther"},{"key":"98_CR161","doi-asserted-by":"publisher","first-page":"379","DOI":"10.3389\/fimmu.2019.00379","volume":"10","author":"V Mollica Poeta","year":"2019","unstructured":"Mollica Poeta V, Massara M, Capucetti A, Bonecchi R. Chemokines and chemokine receptors: new targets for cancer immunotherapy. Front Immunol. 2019;10:379. https:\/\/doi.org\/10.3389\/fimmu.2019.00379.","journal-title":"Front Immunol"},{"issue":"1","key":"98_CR162","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/imr.12432","volume":"272","author":"A Alloatti","year":"2016","unstructured":"Alloatti A, Kotsias F, Magalhaes JG, Amigorena S. Dendritic cell maturation and cross-presentation: timing matters! Immunol Rev. 2016;272(1):97\u2013108. https:\/\/doi.org\/10.1111\/imr.12432.","journal-title":"Immunol Rev"},{"key":"98_CR163","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.imlet.2018.01.011","volume":"196","author":"Q Song","year":"2018","unstructured":"Song Q, Zhang CD, Wu XH. Therapeutic cancer vaccines: from initial findings to prospects. Immunol Lett. 2018;196:11\u201321. https:\/\/doi.org\/10.1016\/j.imlet.2018.01.011.","journal-title":"Immunol Lett"},{"issue":"5","key":"98_CR164","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMoa1001294","volume":"363","author":"PW Kantoff","year":"2010","unstructured":"Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1001294.","journal-title":"N Engl J Med"},{"issue":"6","key":"98_CR165","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/s1470-2045(16)00099-1","volume":"17","author":"JF Vansteenkiste","year":"2016","unstructured":"Vansteenkiste JF, Cho BC, Vanakesa T, De Pas T, Zielinski M, Kim MS, et al. Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2016;17(6):822\u201335. https:\/\/doi.org\/10.1016\/s1470-2045(16)00099-1.","journal-title":"Lancet Oncol"},{"issue":"16","key":"98_CR166","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1016\/j.ejca.2015.07.035","volume":"51","author":"G Giaccone","year":"2015","unstructured":"Giaccone G, Bazhenova LA, Nemunaitis J, Tan M, Juh\u00e1sz E, Ramlau R, et al. A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer. Eur J Cancer. 2015;51(16):2321\u20139. https:\/\/doi.org\/10.1016\/j.ejca.2015.07.035.","journal-title":"Eur J Cancer"},{"issue":"1","key":"98_CR167","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/s1470-2045(13)70510-2","volume":"15","author":"C Butts","year":"2014","unstructured":"Butts C, Socinski MA, Mitchell PL, Thatcher N, Havel L, Krzakowski M, et al. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2014;15(1):59\u201368. https:\/\/doi.org\/10.1016\/s1470-2045(13)70510-2.","journal-title":"Lancet Oncol"},{"issue":"11","key":"98_CR168","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1016\/s1470-2045(16)30408-9","volume":"17","author":"BI Rini","year":"2016","unstructured":"Rini BI, Stenzl A, Zdrojowy R, Kogan M, Shkolnik M, Oudard S, et al. IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2016;17(11):1599\u2013611. https:\/\/doi.org\/10.1016\/s1470-2045(16)30408-9.","journal-title":"Lancet Oncol"},{"key":"98_CR169","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.smim.2018.04.001","volume":"39","author":"SH van der Burg","year":"2018","unstructured":"van der Burg SH. Correlates of immune and clinical activity of novel cancer vaccines. Semin Immunol. 2018;39:119\u201336. https:\/\/doi.org\/10.1016\/j.smim.2018.04.001.","journal-title":"Semin Immunol"},{"issue":"2","key":"98_CR170","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1007\/s11684-022-0922-5","volume":"16","author":"Y Yu","year":"2022","unstructured":"Yu Y. Multi-target combinatory strategy to overcome tumor immune escape. Front Med. 2022;16(2):208\u201315. https:\/\/doi.org\/10.1007\/s11684-022-0922-5.","journal-title":"Front Med"},{"issue":"6","key":"98_CR171","doi-asserted-by":"publisher","first-page":"683","DOI":"10.2217\/imt.15.29","volume":"7","author":"A Esfandiary","year":"2015","unstructured":"Esfandiary A, Ghafouri-Fard S. MAGE-A3: an immunogenic target used in clinical practice. Immunotherapy. 2015;7(6):683\u2013704. https:\/\/doi.org\/10.2217\/imt.15.29.","journal-title":"Immunotherapy."},{"key":"98_CR172","doi-asserted-by":"publisher","first-page":"947","DOI":"10.3389\/fimmu.2018.00947","volume":"9","author":"R Thomas","year":"2018","unstructured":"Thomas R, Al-Khadairi G, Roelands J, Hendrickx W, Dermime S, Bedognetti D, et al. NY-ESO-1 based immunotherapy of cancer: current perspectives. Front Immunol. 2018;9:947. https:\/\/doi.org\/10.3389\/fimmu.2018.00947.","journal-title":"Front Immunol"},{"key":"98_CR173","doi-asserted-by":"publisher","unstructured":"Buonaguro L, Tagliamonte M. Selecting target antigens for cancer vaccine development. Vaccines (Basel). 2020;8(4). https:\/\/doi.org\/10.3390\/vaccines8040615.","DOI":"10.3390\/vaccines8040615"},{"key":"98_CR174","doi-asserted-by":"publisher","unstructured":"Pao SC, Chu MT, Hung SI. Therapeutic vaccines targeting Neoantigens to induce T-cell immunity against cancers. Pharmaceutics. 2022;14(4). https:\/\/doi.org\/10.3390\/pharmaceutics14040867.","DOI":"10.3390\/pharmaceutics14040867"},{"key":"98_CR175","doi-asserted-by":"publisher","unstructured":"Cheng L, Wang Y, Du J. Human papillomavirus vaccines: an updated review. Vaccines (Basel). 2020;8(3). https:\/\/doi.org\/10.3390\/vaccines8030391.","DOI":"10.3390\/vaccines8030391"},{"issue":"9","key":"98_CR176","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1158\/2326-6066.Cir-15-0134","volume":"3","author":"PK Srivastava","year":"2015","unstructured":"Srivastava PK. Neoepitopes of cancers: looking Back, looking ahead. Cancer Immunol Res. 2015;3(9):969\u201377. https:\/\/doi.org\/10.1158\/2326-6066.Cir-15-0134.","journal-title":"Cancer Immunol Res"},{"issue":"8","key":"98_CR177","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41568-019-0162-4","volume":"19","author":"CC Smith","year":"2019","unstructured":"Smith CC, Selitsky SR, Chai S, Armistead PM, Vincent BG, Serody JS. Alternative tumour-specific antigens. Nat Rev Cancer. 2019;19(8):465\u201378. https:\/\/doi.org\/10.1038\/s41568-019-0162-4.","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"98_CR178","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/s41571-020-00460-2","volume":"18","author":"E Blass","year":"2021","unstructured":"Blass E, Ott PA. Advances in the development of personalized neoantigen-based therapeutic cancer vaccines. Nat Rev Clin Oncol. 2021;18(4):215\u201329. https:\/\/doi.org\/10.1038\/s41571-020-00460-2.","journal-title":"Nat Rev Clin Oncol"},{"issue":"7662","key":"98_CR179","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/nature22991","volume":"547","author":"PA Ott","year":"2017","unstructured":"Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J, Bozym DJ, et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 2017;547(7662):217\u201321. https:\/\/doi.org\/10.1038\/nature22991.","journal-title":"Nature."},{"issue":"4","key":"98_CR180","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/nrc.2016.154","volume":"17","author":"M Yarchoan","year":"2017","unstructured":"Yarchoan M, Johnson BA 3rd, Lutz ER, Laheru DA, Jaffee EM. Targeting neoantigens to augment antitumour immunity. Nat Rev Cancer. 2017;17(4):209\u201322. https:\/\/doi.org\/10.1038\/nrc.2016.154.","journal-title":"Nat Rev Cancer"},{"issue":"25","key":"98_CR181","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1056\/NEJMc1713444","volume":"377","author":"M Yarchoan","year":"2017","unstructured":"Yarchoan M, Hopkins A, Jaffee EM. Tumor mutational burden and response rate to PD-1 inhibition. N Engl J Med. 2017;377(25):2500\u20131. https:\/\/doi.org\/10.1056\/NEJMc1713444.","journal-title":"N Engl J Med"},{"key":"98_CR182","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.ejca.2020.02.038","volume":"131","author":"JD Fumet","year":"2020","unstructured":"Fumet JD, Truntzer C, Yarchoan M, Ghiringhelli F. Tumour mutational burden as a biomarker for immunotherapy: current data and emerging concepts. Eur J Cancer. 2020;131:40\u201350. https:\/\/doi.org\/10.1016\/j.ejca.2020.02.038.","journal-title":"Eur J Cancer"},{"key":"98_CR183","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1146\/annurev-immunol-042617-053402","volume":"37","author":"TN Schumacher","year":"2019","unstructured":"Schumacher TN, Scheper W, Kvistborg P. Cancer Neoantigens. Annu Rev Immunol. 2019;37:173\u2013200. https:\/\/doi.org\/10.1146\/annurev-immunol-042617-053402.","journal-title":"Annu Rev Immunol"},{"issue":"6375","key":"98_CR184","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1126\/science.aao4572","volume":"359","author":"D Chowell","year":"2018","unstructured":"Chowell D, Morris LGT, Grigg CM, Weber JK, Samstein RM, Makarov V, et al. Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy. Science. 2018;359(6375):582\u20137. https:\/\/doi.org\/10.1126\/science.aao4572.","journal-title":"Science."},{"issue":"2","key":"98_CR185","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41571-019-0315-0","volume":"17","author":"TV Moore","year":"2020","unstructured":"Moore TV, Nishimura MI. Improved MHC II epitope prediction - a step towards personalized medicine. Nat Rev Clin Oncol. 2020;17(2):71\u20132. https:\/\/doi.org\/10.1038\/s41571-019-0315-0.","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"98_CR186","first-page":"2401","volume":"11","author":"X Wang","year":"2021","unstructured":"Wang X, Yu Z, Liu W, Tang H, Yi D, Wei M. Recent progress on MHC-I epitope prediction in tumor immunotherapy. Am J Cancer Res. 2021;11(6):2401\u201316.","journal-title":"Am J Cancer Res"},{"issue":"6236","key":"98_CR187","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1126\/science.aaa3828","volume":"348","author":"BM Carreno","year":"2015","unstructured":"Carreno BM, Magrini V, Becker-Hapak M, Kaabinejadian S, Hundal J, Petti AA, et al. Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science. 2015;348(6236):803\u20138. https:\/\/doi.org\/10.1126\/science.aaa3828.","journal-title":"Science"},{"key":"98_CR188","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-1-4939-6481-9_1","volume":"1499","author":"T Kramps","year":"2017","unstructured":"Kramps T, Elbers K. Introduction to RNA vaccines. Methods Mol Biol. 2017;1499:1\u201311. https:\/\/doi.org\/10.1007\/978-1-4939-6481-9_1.","journal-title":"Methods Mol Biol"},{"issue":"7662","key":"98_CR189","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/nature23003","volume":"547","author":"U Sahin","year":"2017","unstructured":"Sahin U, Derhovanessian E, Miller M, Kloke BP, Simon P, L\u00f6wer M, et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature. 2017;547(7662):222\u20136. https:\/\/doi.org\/10.1038\/nature23003.","journal-title":"Nature."},{"key":"98_CR190","doi-asserted-by":"publisher","first-page":"114312","DOI":"10.1016\/j.addr.2022.114312","volume":"186","author":"GP Dunn","year":"2022","unstructured":"Dunn GP, Sherpa N, Manyanga J, Johanns TM. Considerations for personalized neoantigen vaccination in malignant glioma. Adv Drug Deliv Rev. 2022;186:114312. https:\/\/doi.org\/10.1016\/j.addr.2022.114312.","journal-title":"Adv Drug Deliv Rev"},{"issue":"18","key":"98_CR191","doi-asserted-by":"publisher","first-page":"4951","DOI":"10.1158\/1078-0432.Ccr-13-0551","volume":"19","author":"WC Rutledge","year":"2013","unstructured":"Rutledge WC, Kong J, Gao J, Gutman DA, Cooper LA, Appin C, et al. Tumor-infiltrating lymphocytes in glioblastoma are associated with specific genomic alterations and related to transcriptional class. Clin Cancer Res. 2013;19(18):4951\u201360. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-13-0551.","journal-title":"Clin Cancer Res"},{"issue":"7738","key":"98_CR192","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1038\/s41586-018-0810-y","volume":"565","author":"N Hilf","year":"2019","unstructured":"Hilf N, Kuttruff-Coqui S, Frenzel K, Bukur V, Stevanovi\u0107 S, Gouttefangeas C, et al. Actively personalized vaccination trial for newly diagnosed glioblastoma. Nature. 2019;565(7738):240\u20135. https:\/\/doi.org\/10.1038\/s41586-018-0810-y.","journal-title":"Nature."},{"issue":"7738","key":"98_CR193","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41586-018-0792-9","volume":"565","author":"DB Keskin","year":"2019","unstructured":"Keskin DB, Anandappa AJ, Sun J, Tirosh I, Mathewson ND, Li S, et al. Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature. 2019;565(7738):234\u20139. https:\/\/doi.org\/10.1038\/s41586-018-0792-9.","journal-title":"Nature."},{"issue":"8","key":"98_CR194","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1158\/2326-6066.Cir-18-0620","volume":"7","author":"KL Lee","year":"2019","unstructured":"Lee KL, Benz SC, Hicks KC, Nguyen A, Gameiro SR, Palena C, et al. Efficient tumor clearance and diversified immunity through Neoepitope vaccines and combinatorial immunotherapy. Cancer Immunol Res. 2019;7(8):1359\u201370. https:\/\/doi.org\/10.1158\/2326-6066.Cir-18-0620.","journal-title":"Cancer Immunol Res"},{"key":"98_CR195","doi-asserted-by":"publisher","unstructured":"Kinkead HL, Hopkins A, Lutz E, Wu AA, Yarchoan M, Cruz K, et al. Combining STING-based neoantigen-targeted vaccine with checkpoint modulators enhances antitumor immunity in murine pancreatic cancer. JCI Insight. 2018;3(20). https:\/\/doi.org\/10.1172\/jci.insight.122857.","DOI":"10.1172\/jci.insight.122857"},{"key":"98_CR196","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1146\/annurev-med-062518-045435","volume":"71","author":"RH Vonderheide","year":"2020","unstructured":"Vonderheide RH. CD40 agonist antibodies in cancer immunotherapy. Annu Rev Med. 2020;71:47\u201358. https:\/\/doi.org\/10.1146\/annurev-med-062518-045435.","journal-title":"Annu Rev Med"},{"key":"98_CR197","doi-asserted-by":"publisher","unstructured":"Lhuillier C, Rudqvist NP, Yamazaki T, Zhang T, Charpentier M, Galluzzi L, et al. Radiotherapy-exposed CD8+ and CD4+ neoantigens enhance tumor control. J Clin Invest. 2021;131(5). https:\/\/doi.org\/10.1172\/jci138740.","DOI":"10.1172\/jci138740"},{"key":"98_CR198","doi-asserted-by":"publisher","unstructured":"Lussier DM, Alspach E, Ward JP, Miceli AP, Runci D, White JM, et al. Radiation-induced neoantigens broaden the immunotherapeutic window of cancers with low mutational loads. Proc Natl Acad Sci U S A. 2021;118(24). https:\/\/doi.org\/10.1073\/pnas.2102611118.","DOI":"10.1073\/pnas.2102611118"},{"issue":"4","key":"98_CR199","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1007\/s00262-020-02729-y","volume":"70","author":"KL Lee","year":"2021","unstructured":"Lee KL, Schlom J, Hamilton DH. Combination therapies utilizing neoepitope-targeted vaccines. Cancer Immunol Immunother. 2021;70(4):875\u201385. https:\/\/doi.org\/10.1007\/s00262-020-02729-y.","journal-title":"Cancer Immunol Immunother"},{"issue":"127","key":"98_CR200","doi-asserted-by":"publisher","first-page":"127ra37","DOI":"10.1126\/scitranslmed.3003689","volume":"4","author":"JM Taube","year":"2012","unstructured":"Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL, et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med. 2012;4(127):127ra37. https:\/\/doi.org\/10.1126\/scitranslmed.3003689.","journal-title":"Sci Transl Med"},{"issue":"8","key":"98_CR201","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1158\/2326-6066.Cir-14-0206","volume":"3","author":"BT Rekoske","year":"2015","unstructured":"Rekoske BT, Smith HA, Olson BM, Maricque BB, McNeel DG. PD-1 or PD-L1 blockade restores antitumor efficacy following SSX2 epitope-modified DNA vaccine immunization. Cancer Immunol Res. 2015;3(8):946\u201355. https:\/\/doi.org\/10.1158\/2326-6066.Cir-14-0206.","journal-title":"Cancer Immunol Res"},{"issue":"7528","key":"98_CR202","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/nature14001","volume":"515","author":"M Yadav","year":"2014","unstructured":"Yadav M, Jhunjhunwala S, Phung QT, Lupardus P, Tanguay J, Bumbaca S, et al. Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature. 2014;515(7528):572\u20136. https:\/\/doi.org\/10.1038\/nature14001.","journal-title":"Nature."},{"issue":"6","key":"98_CR203","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/ni.2035","volume":"12","author":"EJ Wherry","year":"2011","unstructured":"Wherry EJ. T cell exhaustion. Nat Immunol. 2011;12(6):492\u20139. https:\/\/doi.org\/10.1038\/ni.2035.","journal-title":"Nat Immunol"},{"issue":"11","key":"98_CR204","doi-asserted-by":"publisher","first-page":"2734","DOI":"10.1158\/1078-0432.Ccr-15-2361","volume":"22","author":"M Leisegang","year":"2016","unstructured":"Leisegang M, Engels B, Schreiber K, Yew PY, Kiyotani K, Idel C, et al. Eradication of large solid tumors by gene therapy with a T-cell receptor targeting a single cancer-specific point mutation. Clin Cancer Res. 2016;22(11):2734\u201343. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-15-2361.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"98_CR205","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s40425-019-0629-6","volume":"7","author":"S Liu","year":"2019","unstructured":"Liu S, Matsuzaki J, Wei L, Tsuji T, Battaglia S, Hu Q, et al. Efficient identification of neoantigen-specific T-cell responses in advanced human ovarian cancer. J Immunother Cancer. 2019;7(1):156. https:\/\/doi.org\/10.1186\/s40425-019-0629-6.","journal-title":"J Immunother Cancer"},{"issue":"6449","key":"98_CR206","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1126\/science.aav8692","volume":"365","author":"L Ma","year":"2019","unstructured":"Ma L, Dichwalkar T, Chang JYH, Cossette B, Garafola D, Zhang AQ, et al. Enhanced CAR-T cell activity against solid tumors by vaccine boosting through the chimeric receptor. Science. 2019;365(6449):162\u20138. https:\/\/doi.org\/10.1126\/science.aav8692.","journal-title":"Science."},{"issue":"6","key":"98_CR207","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/s0369-8114(01)00172-9","volume":"49","author":"C Maliszewski","year":"2001","unstructured":"Maliszewski C. Dendritic cells in models of tumor immunity. Role of Flt3 ligand. Pathol Biol (Paris). 2001;49(6):481\u20133. https:\/\/doi.org\/10.1016\/s0369-8114(01)00172-9.","journal-title":"Pathol Biol (Paris)"},{"issue":"19","key":"98_CR208","doi-asserted-by":"publisher","first-page":"6132","DOI":"10.1158\/0008-5472.Can-11-0291","volume":"71","author":"S Kreiter","year":"2011","unstructured":"Kreiter S, Diken M, Selmi A, Diekmann J, Attig S, H\u00fcsemann Y, et al. FLT3 ligand enhances the cancer therapeutic potency of naked RNA vaccines. Cancer Res. 2011;71(19):6132\u201342. https:\/\/doi.org\/10.1158\/0008-5472.Can-11-0291.","journal-title":"Cancer Res"},{"issue":"4","key":"98_CR209","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/s41581-019-0244-2","volume":"16","author":"KT Mills","year":"2020","unstructured":"Mills KT, Stefanescu A, He J. The global epidemiology of hypertension. Nat Rev Nephrol. 2020;16(4):223\u201337. https:\/\/doi.org\/10.1038\/s41581-019-0244-2.","journal-title":"Nat Rev Nephrol"},{"issue":"2","key":"98_CR210","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/s41371-021-00570-z","volume":"36","author":"R Yin","year":"2022","unstructured":"Yin R, Yin L, Li L, Silva-Nash J, Tan J, Pan Z, et al. Hypertension in China: burdens, guidelines and policy responses: a state-of-the-art review. J Hum Hypertens. 2022;36(2):126\u201334. https:\/\/doi.org\/10.1038\/s41371-021-00570-z.","journal-title":"J Hum Hypertens"},{"key":"98_CR211","doi-asserted-by":"publisher","first-page":"1638462","DOI":"10.1155\/2018\/1638462","volume":"2018","author":"K Lu","year":"2018","unstructured":"Lu K, Su B, Meng X. Recent advances in the development of vaccines for diabetes, hypertension, and atherosclerosis. J Diabetes Res. 2018;2018:1638462. https:\/\/doi.org\/10.1155\/2018\/1638462.","journal-title":"J Diabetes Res"},{"issue":"5","key":"98_CR212","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1046\/j.1365-2125.2003.01926.x","volume":"56","author":"MR Downham","year":"2003","unstructured":"Downham MR, Auton TR, Rosul A, Sharp HL, Sjostrom L, Rushton A, et al. Evaluation of two carrier protein-angiotensin I conjugate vaccines to assess their future potential to control high blood pressure (hypertension) in man. Br J Clin Pharmacol. 2003;56(5):505\u201312. https:\/\/doi.org\/10.1046\/j.1365-2125.2003.01926.x.","journal-title":"Br J Clin Pharmacol"},{"issue":"9615","key":"98_CR213","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/S0140-6736(08)60381-5","volume":"371","author":"AC Tissot","year":"2008","unstructured":"Tissot AC, Maurer P, Nussberger J, Sabat R, Pfister T, Ignatenko S, et al. Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study. Lancet. 2008;371(9615):821\u20137. https:\/\/doi.org\/10.1016\/S0140-6736(08)60381-5.","journal-title":"Lancet."},{"issue":"3","key":"98_CR214","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s10741-020-10033-1","volume":"26","author":"NF Garay-Guti\u00e9rrez","year":"2021","unstructured":"Garay-Guti\u00e9rrez NF, Hernandez-Fuentes CP, Garc\u00eda-Rivas G, Lavandero S, Guerrero-Beltr\u00e1n CE. Vaccines against components of the renin-angiotensin system. Heart Fail Rev. 2021;26(3):711\u201326. https:\/\/doi.org\/10.1007\/s10741-020-10033-1.","journal-title":"Heart Fail Rev"},{"key":"98_CR215","doi-asserted-by":"publisher","unstructured":"Global, regional, and national burden of neurological disorders, 1990-2016: a systematic analysis for the global burden of disease study 2016. Lancet Neurol. 2019;18(5):459\u201380. https:\/\/doi.org\/10.1016\/s1474-4422(18)30499-x.","DOI":"10.1016\/s1474-4422(18)30499-x"},{"key":"98_CR216","doi-asserted-by":"publisher","first-page":"15056","DOI":"10.1038\/nrdp.2015.56","volume":"1","author":"CL Masters","year":"2015","unstructured":"Masters CL, Bateman R, Blennow K, Rowe CC, Sperling RA, Cummings JL. Alzheimer's disease. Nat Rev Dis Primers. 2015;1:15056. https:\/\/doi.org\/10.1038\/nrdp.2015.56.","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"98_CR217","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s00401-014-1375-y","volume":"129","author":"DR Thal","year":"2015","unstructured":"Thal DR, Walter J, Saido TC, F\u00e4ndrich M. Neuropathology and biochemistry of A\u03b2 and its aggregates in Alzheimer's disease. Acta Neuropathol. 2015;129(2):167\u201382. https:\/\/doi.org\/10.1007\/s00401-014-1375-y.","journal-title":"Acta Neuropathol"},{"issue":"7","key":"98_CR218","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41582-018-0013-z","volume":"14","author":"EE Congdon","year":"2018","unstructured":"Congdon EE, Sigurdsson EM. Tau-targeting therapies for Alzheimer disease. Nat Rev Neurol. 2018;14(7):399\u2013415. https:\/\/doi.org\/10.1038\/s41582-018-0013-z.","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"98_CR219","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13195-018-0340-8","volume":"10","author":"AM Lacosta","year":"2018","unstructured":"Lacosta AM, Pascual-Lucas M, Pesini P, Casabona D, P\u00e9rez-Grijalba V, Marcos-Campos I, et al. Safety, tolerability and immunogenicity of an active anti-A\u03b2(40) vaccine (ABvac40) in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase I trial. Alzheimers Res Ther. 2018;10(1):12. https:\/\/doi.org\/10.1186\/s13195-018-0340-8.","journal-title":"Alzheimers Res Ther"},{"issue":"4","key":"98_CR220","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/alzrt278","volume":"6","author":"E Kontsekova","year":"2014","unstructured":"Kontsekova E, Zilka N, Kovacech B, Novak P, Novak M. First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer's disease model. Alzheimers Res Ther. 2014;6(4):44. https:\/\/doi.org\/10.1186\/alzrt278.","journal-title":"Alzheimers Res Ther"},{"issue":"2","key":"98_CR221","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/s1474-4422(16)30331-3","volume":"16","author":"P Novak","year":"2017","unstructured":"Novak P, Schmidt R, Kontsekova E, Zilka N, Kovacech B, Skrabana R, et al. Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Neurol. 2017;16(2):123\u201334. https:\/\/doi.org\/10.1016\/s1474-4422(16)30331-3.","journal-title":"Lancet Neurol"},{"issue":"2","key":"98_CR222","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.trci.2017.03.005","volume":"3","author":"CY Wang","year":"2017","unstructured":"Wang CY, Wang PN, Chiu MJ, Finstad CL, Lin F, Lynn S, et al. UB-311, a novel UBITh(\u00ae) amyloid \u03b2 peptide vaccine for mild Alzheimer's disease. Alzheimers Dement (N Y). 2017;3(2):262\u201372. https:\/\/doi.org\/10.1016\/j.trci.2017.03.005.","journal-title":"Alzheimers Dement (N Y)"},{"issue":"5","key":"98_CR223","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1007\/s12325-009-0030-9","volume":"26","author":"CF Deacon","year":"2009","unstructured":"Deacon CF, Holst JJ. Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes. Adv Ther. 2009;26(5):488\u201399. https:\/\/doi.org\/10.1007\/s12325-009-0030-9.","journal-title":"Adv Ther"},{"key":"98_CR224","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.lfs.2017.11.021","volume":"192","author":"Y Zhang","year":"2018","unstructured":"Zhang Y, Yu XL, Zha J, Mao LZ, Chai JQ, Liu RT. Therapeutic vaccine against IL-1\u03b2 improved glucose control in a mouse model of type 2 diabetes. Life Sci. 2018;192:68\u201374. https:\/\/doi.org\/10.1016\/j.lfs.2017.11.021.","journal-title":"Life Sci"},{"key":"98_CR225","doi-asserted-by":"publisher","first-page":"401","DOI":"10.3389\/fimmu.2020.00401","volume":"11","author":"RC Hoogeveen","year":"2020","unstructured":"Hoogeveen RC, Boonstra A. Checkpoint inhibitors and therapeutic vaccines for the treatment of chronic HBV infection. Front Immunol. 2020;11:401. https:\/\/doi.org\/10.3389\/fimmu.2020.00401.","journal-title":"Front Immunol"},{"issue":"1","key":"98_CR226","doi-asserted-by":"publisher","first-page":"e1003856","DOI":"10.1371\/journal.ppat.1003856","volume":"10","author":"J Liu","year":"2014","unstructured":"Liu J, Zhang E, Ma Z, Wu W, Kosinska A, Zhang X, et al. Enhancing virus-specific immunity in vivo by combining therapeutic vaccination and PD-L1 blockade in chronic hepadnaviral infection. PLoS Pathog. 2014;10(1):e1003856. https:\/\/doi.org\/10.1371\/journal.ppat.1003856.","journal-title":"PLoS Pathog"}],"container-title":["Molecular Biomedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43556-022-00098-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43556-022-00098-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43556-022-00098-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T03:04:14Z","timestamp":1670468654000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s43556-022-00098-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,8]]},"references-count":226,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["98"],"URL":"https:\/\/doi.org\/10.1186\/s43556-022-00098-9","relation":{},"ISSN":["2662-8651"],"issn-type":[{"value":"2662-8651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,8]]},"assertion":[{"value":"5 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors have declared that no competing interest exist.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"40"}}